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1 Abstract	  
Cancer Stem Cells (CSCs) are a clinically relevant population at the apex of the inner 
hierarchical organization of many tumors. It was previously demonstrated by our group 
that loss of the p53 tumor suppressor leads to an increase in the mammary stem cell 
(MaSC) and breast CSC content, due to a switch of the mode of division from mainly 
asymmetric to symmetric. However, which of the many pathways instructed by p53 is 
directly involved in the execution of this biological phenotype remains to be determined. 
Following a candidate gene approach, we investigated Myc as the putative key 
downstream effector of p53 in breast SCs and CSCs. The Myc oncogene is very often 
altered in cancer and has been clinically associated with poor differentiation and 
aggressiveness in breast cancer. We have found that Myc endogenous expression is de-
regulated in our ErbB2 model of breast tumorigenesis, upon attenuation of p53 signaling. 
We also observed that de-regulated Myc extends the lifespan and proliferative potential of 
wild type mammospheres. This occurs by two distinct but cooperative mechanisms: the 
increase in the frequency of symmetric divisions of MaSCs and the reprogramming of 
progenitor cells. Importantly, in the ErbB2 model, de-regulated Myc levels are critical and 
sufficient to sustain the unlimited self-renewal of CSCs, independently of p53. Of note, the 
above described phenotype is characterized by the over expression of a mitotic gene 
signature which is dictated by the identified p53-Myc axis.   
Taken together these results demonstrate that the loss of a tight control on Myc levels, 
which derives from the loss of p53 functionality, is responsible for the expansion of the SC 
and CSC pool by regulating modality of SC division and reprogramming of mammary 
progenitors. Finally, our data suggest that the p53-Myc axis exerts a putative tumor 
suppressor function in SCs through the coordinated regulation of a set of mitotic genes. 
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2 Introduction	  
 
2.1 The	  heterogeneous	  nature	  of	  cancer	  
 
Cancer is a very widespread disease and represents one of the leading causes of death in 
the modern era. Based on 2012 estimates the GLOBOCAN program predicted a 
considerable increase to 19.3 million new cancer cases per year by 2025, due to growth 
and ageing of the global population. Despite the many advances made in terms of 
therapeutic options for patients, which have led to a consistent increase in the “tumor free 
time window”, cancer recurrence is still a very frequent event, often mortal.  
It is becoming more and more clear that cancer cannot be considered a single disease, as it 
is extremely heterogeneous, from tissue to tissue and from patient to patient. Intra-tumor 
heterogeneity, in particular, is a key source of complexity that ultimately leads to tumor 
progression, therapy resistance and cancer recurrence. Tumors are increasingly seen as 
ecosystems containing both malignant cells and infiltrating endothelial, hematopoietic, 
stromal, and other cell types that all together go under the definition of 
“microenvironment” and can influence the function of the tumor as a whole (Junttila and 
de Sauvage 2013). As an ecosystem, the inner nature of tumors is to evolve in response to 
cell-autonomous and non cell-autonomous stimuli that aim at increasing its fitness and that 
eventually lead to variations in the cellular processes of growth, metabolism, apoptosis and 
other “hallmarks of cancer” (Hanahan and Weinberg 2011).  
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Two main models have been proposed to dissect the mechanisms by which tumors evolve: 
the first is the Cancer Stem Cells (CSCs) theory that predicts an inherent functional 
heterogeneity among tumor cells; the second is the clonal evolution model that is based 
mainly on the observed genetic heterogeneity within tumors. Both models harbor strengths 
and limitations which I will try to summarize in the following section. 
 
2.1.1 The	  Cancer	  Stem	  Cell	  theory,	  past	  and	  present	  
 
The cancer stem cells model of tumor evolution predicts the existence, within a given 
tumor, of a cell population that is at the apex of a functional and developmental hierarchy, 
the so-called Cancer Stem Cells (CSCs). As the name implies, these cells are believed to 
share many properties with the stem cells (SCs) that compose normal tissues (normal SCs), 
above all, self-renewal ability (potential to generate new CSCs), multi-lineage capacity 
(ability to generate non-CSC) and quiescent nature. Therefore, the tumor is understood as a 
functionally organized entity with the CSC being the only population able to sustain tumor 
progression and, potentially, being responsible of relapse upon pharmacological therapies. 
The existence of this hierarchy was first demonstrated in acute myeloid leukemia by the 
pioneering work of John Dick’s lab (Lapidot, Sirard et al. 1994). In this study, the authors 
showed that only a rare population of leukemic cells, which were positive for the CD34 
surface marker and negative for the CD38 antigen, was able to seed a tumor upon 
xenotransplantation in immuno-compromised hosts. Later on, many other works 
demonstrated the existence of such tumorigenic populations also in solid tumors, taking 
advantage of cell type specific surface markers. In particular, the validity of the CSC 
theory was reported first in human breast cancer (Al-Hajj, Wicha et al. 2003), and then in 
numerous other tumors, including glioblastoma (Singh, Hawkins et al. 2004), pancreatic 
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cancer (Hermann, Huber et al. 2007), lung cancer (Eramo, Lotti et al. 2008), prostate 
cancer (Patrawala, Calhoun et al. 2006), colorectal cancer (O'Brien, Pollett et al. 2007). All 
these works rely on the transplantation, in murine hosts, of isolated cell populations which 
are then proven tumorigenic (they are therefore also known as TICs, tumor initiating cells) 
and capable to give rise to a progeny of non-TICs, thus providing evidence for a 
hierarchical organization. 
The CSCs theory has remarkable implications for therapeutic strategies aimed at curing 
cancer. Indeed, these cells seem to possess all the clinically relevant features that 
determine cancer maintenance, drive cancer heterogeneity, and cause resistance to 
conventional drug regimens. In line with this, gene expression signatures specific to CSCs 
and normal SCs are prognostic of patients’ disease outcomes, regardless of their genetic 
landscape (Ben-Porath, Thomson et al. 2008, Eppert, Takenaka et al. 2011, Merlos-Suárez, 
Barriga et al. 2011). The work of Ben-Porath and colleagues was one of the first to explore 
this correlation. The study hypothesized that the un-differentiated stage of breast cancer 
could be driven by the combined expression of oncogenes and SC-associated genes; the 
authors showed that an embryonic stem cell (ESC) gene signature is enriched in human 
tumors, particularly in poorly differentiated (grade 3) breast tumors. The ESC gene 
signature included under-expression of Polycomb target gene sets and over-expression of 
ES-expressed sets, while the well differentiated grade 1 tumors displayed an opposite 
pattern (Ben-Porath, Thomson et al. 2008). 
Not only gene signatures from ES cells, but also gene expression profiles of adult normal 
SCs and validated CSCs were proven to correlate with prognostic parameters. In the study 
of Eppert and colleagues, 16 primary human acute myeloid leukemia (AML) samples were 
tested for the presence of leukemic stem cell (LSCs) populations by the use of a classic 
combination of CD34 and CD38 surface markers (Bonnet and Dick 1997). Once found, the 
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putative LSCs were validated functionally in transplantation assay and their gene 
expression profile was assessed by microarray analysis, in parallel with normal human 
hematopoietic stem cells (HSCs). The expression profiles of the two populations resulted 
very similar and were shown to positively correlate with groups of patients expressing 
molecular markers of poor prognosis (like FLT3ITD) and to be highly expressed in high 
risk subjects (Eppert, Takenaka et al. 2011).  
The same types of conclusions were also shown to be valid for solid cancers. For example, 
Merlos-Suarez et al. demonstrated that a gene signature specific for adult intestinal stem 
cells predicts disease relapse in colorectal cancer patients (Merlos-Suárez, Barriga et al. 
2011).  
All these findings demonstrate that “stemness” is a crucial biological property for cancer 
cells and their sustainment. Indeed, despite the fact that numbers of CSCs may vary greatly 
across different tumors, and that the identified markers cannot be universally applied, it 
appears clear that the content of CSCs and/or their associated expression program correlate 
with the aggressiveness of the disease. One study clearly shows the applicability of this 
concept to breast cancer (Pece, Tosoni et al. 2010): high grade estrogen receptor- negative 
tumors (G3/ER-) are enriched in CSCs, as demonstrated by mammosphere culture and 
tranplantation assays.  
Furthermore, CSCs are also intrinsically resistant to therapies. In chronic myeloid 
leukemia (CML), LSCs are able to survive imatinib treatment independently of the 
presence of resistance-associated mutations in the BCR-ABL gene and of the selective 
inhibition of the fusion protein, suggesting that they are not oncogene-addicted like the 
non-LSC population (Corbin, Agarwal et al. 2011). A similar scenario also occurs with 
classic chemotherapy drugs: a clinical study in breast cancer showed that docetaxel or 
doxorubicin treatment leads to a significant increase in the percentage of CD44+/CD24- 
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cells (putative CSCs) (Al-Hajj, Wicha et al. 2003), from a mean of 4.7% at baseline to 
13.6%, regardless of the molecular subtype (Li, Lewis et al. 2008). Furthermore, breast 
CSCs were also shown to be resistant to radiotherapy: murine models of spontaneous 
breast cancer (MMTV-Wnt1 mice) were treated with courses of ionizing radiation and the 
percentage of CSCs (defined in this model as Thy1+CD24+Lin- cells) was found to be 
consistently increased compared to the non-TIC fraction (Diehn, Cho et al. 2009). 
Several molecular processes underlying differential sensitivities among hierarchically 
organized tumor cells have been proposed, including up-regulation of anti-apoptotic 
molecules and lower content of reactive oxygen species, with consequent less 
accumulation of DNA damage; however, a full understanding of CSC specific mechanisms 
is still lacking. 
Taken together, all these finding demonstrate that CSCs are clinically relevant entities and 
that therapeutic strategies intended to kill them would be extremely beneficial for complete 
disease eradication. Nevertheless, the concept of a hierarchical structure inherent to tumors 
has been challenged in recent years by new experimental approaches that dissected other 
sources of tumor heterogeneity, such as genetic evolution, complexity of the 
microenvironment cross talks, and reversible changes in CSC properties. 
 
2.1.2 The	  clonal	  evolution	  model	  
 
One major criticism towards the CSC theory regards the validity of the gold standard assay 
that defines CSC properties, that is, the transplantation procedure. The process of 
implanting cells in a host is, physiologically, a profound barrier to tumor development as it 
measures the tumorigenic potential on the base of a permissive environment. In order to 
avoid the xenogeneic immune response that would kill human cells in mice, mouse strains 
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with various degrees of immune dysfunction (immune-compromised mice) have been 
employed; notably, the frequency of CSCs varies a lot after transplantations in these mice, 
being much higher in more severely immunodeficient mice (Quintana, Shackleton et al. 
2008, Ishizawa, Rasheed et al. 2010). Syngeneic transplantation of murine tumors has 
given support to the CSC theory, confirming their existence in the absence of an 
immunological barrier to engraftment.  
Another limitation of the model is that it relies entirely on the presence/absence of surface 
markers both for defining the CSCs and for showing the generation of their heterogeneous 
progeny. This has two main implications: first, it does not take into consideration the 
variability among patients and, second, it does not prove that the genetic heterogeneity of 
the tumor is fully recapitulated by the SC progeny. Indeed, it was shown for some tumors 
that the identified markers are not predictive of CSC functions, while for others it is clear 
that they do not work for all patients and tumor subtypes (Meacham and Morrison 2013). 
For example, it is not true for all AML patients that the CD38-/CD34+ population is the 
most enriched in CSCs, as other fractions of cells were also shown to be tumorigenic 
(Eppert, Takenaka et al. 2011). 
Indeed, tumor heterogeneity could also arise when the cells composing the tumor differ 
genetically. If this were the case, transformation could occur through the accumulation of 
multiple stochastic genetic mutations that are selected by tumor evolution because they 
provide a survival advantage to the cell. The result is the generation of a heterogeneous 
population of cancer cells within the same tumor: this model has been named the clonal 
evolution model. 
Recent works of genome sequencing have confirmed this concept. Indeed, it was recently 
demonstrated that, within a single patient, a cancer is composed of genetically distinct sub-
clones that arise through branching evolution and that possess different mutations which, 
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in turn, can differently contribute to cancer development and, so, give rise to functional 
heterogeneity (Kreso and Dick 2014). New sub-clones survive if they are fit enough for the 
tumor environment, otherwise they can be completely lost, dominated by the fittest clone; 
some minor sub-clones, though, can persist alongside the dominant one, supporting its 
growth or acting as a reservoir of genetic diversity from which evolution can continue 
(Kreso and Dick 2014).  
In this context, the anti-cancer therapy could represent an external stimulus for the 
selection of mutations that confer resistance on the tumor clone, thus ensuring its survival.  
Therefore, the clonal evolution model can explain several features of cancer, including its 
morphological and functional heterogeneity, tumor progression and recurrence. 
Nevertheless, a recent study demonstrated that even within a single genetic clone, cancer 
cells retain functional heterogeneity (Kreso, O'Brien et al. 2013). In this work, the authors 
isolated individual subclones from patients’ colorectal cancer and propagated them in 
xenografts, creating monogenetic cancer lineages. The tumor cells in each lineage, marked 
by a lentiviral system, exhibited a very wide spectrum of behaviors in terms of 
proliferative potential and ability to survive to serial passages. Furthermore, upon 
treatment of the mice with conventional chemotherapy, the authors observed that only cells 
with a low proliferative index (i.e., quiescent) were able to survive and contribute to tumor 
regrowth, without selection of new genetic subclones (Kreso, O'Brien et al. 2013). 
Thus, these results directly identify functional diversity among cells that are part of a 
single genetic clone and add a new layer of complexity to our attempts to dissect the 
heterogeneous nature of tumors (Figure 2-1). 
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Figure 2-1: Functional heterogeneity within cancer genetic sub-clones (Kreso et al. 2014) Copyright © 
2014 Elsevier Inc. All rights reserved. 
 
Given all the available knowledge about tumor evolution, it seems reasonable to 
hypothesize that hierarchical organization and clonal evolution coexist during tumor 
progression. Regardless of the type of evolution that tumors undergo, it appears that 
“stemness”, intended as an undifferentiated state of cells which are capable of self-renewal 
and giving rise to long-lived clones of propagating cells, is a key property of cancer. 
Therefore, the dissection of self-renewal specific mechanisms (in SCs and in CSCs) might 
help us to understand the alterations that are at the basis of carcinogenesis and lead to more 
efficient anti-cancer therapies.  
In the next section, we will examine the de-regulation of specific SC pathways in the 
mammary gland tissue and how much they are predictive of malignant transformation. 
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2.2 Mammary	  stem	  cells	  and	  breast	  cancer	  stem	  cells	  
2.2.1 Mammary	  gland	  physiology	  and	  mammary	  stem	  cells	  
 
The mammary gland is a very unique organ in the female body and undergoes complex 
morphological changes and re-arrangements in response to reproductive and hormonal 
stimuli for which it is required a high level of dynamicity. It is composed of two tissue 
compartments: the epithelium, made of ductal and alveolar cells, and the stroma, that 
mainly consists of adipocytes together with fibroblasts and infiltrating hematopoietic cells. 
The epithelium is organized in a system of branched ducts terminating in lobular structures 
or alveoli which represent the core of the secretive function. The ducts are composed of 
two cellular types: the luminal cells, which express the cytokeratins 8 and 18 (K8/K18), 
reside around the central lumen, and terminally specialize in the production of milk at 
pregnancy, and the outer basal-myoepithelial cells, which express the keratins 5 and 14 
(K5/14) and are located in proximity of the basement membrane where they contract to 
facilitate milk release (Figure 2-2).    
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Figure 2-2: Composition of mammary gland epithelium. © 2014 Visvader and Stingl; Published by Cold 
Spring Harbor Laboratory Press 
 
 
The epithelial branching of the mammary gland starts at puberty, when sex hormones 
signaling stimulate the elongation of terminal lobular units and end buds (TEBs) so that 
they can penetrate the fat pad. During pregnancy, the gland reaches its full differentiation 
capacity, with the expansion and maturation of the alveolar compartment that lead to the 
secretion of milk during lactation (Figure 2-3). Lactation is followed by an involution 
stage, during which the alveoli undergo apoptosis and remodeling to restore a simple 
ductal structure. This complex cycle of rearrangements is repeated at every new pregnancy, 
suggesting the existence of a cellular reservoir which sustains and regenerates the tissue 
and is able to self-renew and give rise to a multi-specialized progeny. Therefore, it seems 
reasonable to hypothesize a differentiation hierarchy within the mammary gland tissue, 
with mammary stem cells (MaSCs) at its apex.  
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Figure 2-3: Series of re-arrangements through which the mammary gland tissue undergoes. 
(Hennighausen & Robinson 2005) Copyright © 2005 Nature Publishing Group 
 
In 2006, two pioneering works led to the isolation of a population of cells enriched in 
MaSCs in the murine gland, as demonstrated by transplantation assays and by multi-
lineage differentiation ability (Shackleton, Vaillant et al. 2006, Stingl, Eirew et al. 2006). 
This cell population was characterized by the expression of a combination of surface 
markers such as: low levels of Sca-1, CD24 (heat-stable antigen) and high levels of CD49f 
(α6 integrin) or CD29 (β1 integrin) (Sca-1neg/ CD24med/+CD49fhi/CD29hi) and was shown 
to be resident in the basal/myoepithelial layer on the epithelial ducts. Later works have 
shown that MaSCs can be preferentially enriched over other basal cells based on their 
higher expression levels of CD24 or CD61 (β3 integrin), and EpCAM (Visvader and Stingl 
2014). 
Recently, however, the concept of multi-potent SCs in the mammary gland has been 
challenged by one work in which the cell fate of basal and luminal cells was followed in 
situ in a so-called lineage tracing experiment. The study was based on basal (K14/K5) and 
luminal (K18/K8) keratins-inducible mouse models and demonstrated that both the 
myoepithelial and the luminal compartments contain long living unipotent SCs that sustain 
the development of the adult mammary gland during puberty and pregnancy, without any 
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evidence of the existence of rare multipotent SCs (Van Keymeulen, Rocha et al. 2011). 
These findings have been subjected to a long debate and were challenged by at least two 
independent works. These studies, while highlighting, with independent lineage-tracing 
approaches, the existence of MaSCs with multi-lineage capacity coordinating the 
homeostasis of the adult murine gland, conceded that unipotent long-lived progenitors 
might cooperate with SCs in the pubertal dynamics (van Amerongen, Bowman et al. 2012, 
Rios, Fu et al. 2014).   
More recently, a study by Wang et al. (Wang, Cai et al. 2015) has identified the protein C 
receptor (ProcR) as a unique marker of MaSCs (assessed by both lineage tracing and 
transplantation assays). This marker characterizes a MaSC population that is at the top of 
the functional and developmental hierarchy, supporting a model in which unipotent and 
multipotent MaSCs could coexist in the adult mammary gland, thus reconciling the 
opposite views emerged from previous lineage tracing studies (Figure 2-4).  
 
Figure 2-4: Hierarchical organization of the mammary epithelium. Wang et al. 2015 © 2014 Macmillan 
Publishers Limited. All Rights Reserved. 
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Another strategy which has been employed in the effort to isolate and characterize MaSCs 
is that of exploiting their quiescent or slowly proliferating nature. To this end, researches 
have taken advantage of a label-retaining assay based on the incorporation of a liphophilic 
fluorescent dye (PKH-26) which binds the cell membrane and whose fluorescent intensity 
gets diluted at every cell division. Therefore, actively cycling cells rapidly become 
negative for the dye, while slowly proliferating cells retain it. It was shown that, by this 
technique, it is possible to isolate a highly enriched population of MaSCs, as assessed by 
limiting dilution transplantation (SC frequency = 1:4) (Cicalese, Bonizzi et al. 2009, Pece, 
Tosoni et al. 2010).  
The perspective isolation of bona fide MaSCs has important implications not only for the 
understanding of the complex developmental dynamics within the tissue, but also because 
de-regulation of SC specific processes is known to lead to malignant transformation 
(Visvader 2009). 
 
2.2.2 Breast	  cancer	  stem	  cells	  
 
Since the 2008 estimates, breast cancer incidence has increased by more than 20%, while 
mortality has increased by 14%. Breast cancer is also the most common cause of cancer 
death among women (522,000 deaths in 2012) and the most frequently diagnosed cancer 
among women worldwide (Globocan, 2012).  
Breast tumor is a highly heterogeneous disease that comprises many different pathological 
and molecular subtypes. Indeed, it is now categorized into at least five different subtypes 
based on distinct gene expression signatures that correlate with patient outcome (Reis-
Filho and Pusztai 2011), representing a major challenge for the research of efficacious 
therapies. It is believed that the wide inter-tumor heterogeneity is a reflection of the 
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different “cells of origin” that drove the malignant transformation. This is why the 
dissection of the hierarchical structure of the normal epithelium is fundamental for 
understanding tumor development. In this context, SC defining properties of self-renewal 
and self-maintenance makes these cells prospective candidates in the search for the 
potential cells of origin of cancer, although there is also considerable evidence that 
progenitors too can be targets of the transformation process (Visvader and Stingl 2014). 
The human breast cancer was the first solid malignancy for which the cancer stem model 
was described. Breast cancer SCs were isolated based on the expression of the cell surface 
markers ESA and CD44 and on the absence of CD24 (Al-Hajj, Wicha et al. 2003). Since 
then, other markers have been described to isolate human breast CSCs, as, for example, 
aldehyde dehydrogenase (ALDH) (Ginestier, Hur et al. 2007), whose expression correlated 
with aggressiveness and metastatic potential (Charafe-Jauffret, Ginestier et al. 2010). 
Furthermore, in transgenic models of spontaneous breast tumors, the same surface markers 
that were found to enrich for normal SCs, were also predictive of CSC functions. In details, 
CSC enrichment was reported: i) in the CD24posThy1pos (Cho, Wang et al. 2008) and in 
the CD29lowCD24posCD61pos (Vaillant, Asselin-Labat et al. 2008) breast cancer 
fractions derived from MMTV-Wnt-1 transgenic mice; ii) in the CD24highCD29high 
populations from p53-null mice (Zhang, Behbod et al. 2008). Perspective isolation of 
CSCs was also documented in a model of murine tumorigenesis driven by a mutated form 
of the ErbB2 gene (MMTV-NeuT), in which the positivity to the surface marker Sca1 
(Sca1+) selects a tumorigenic population of cells over a non tumorigenic one (Grange, 
Lanzardo et al. 2008). 
However, as we already discussed, surface markers have shown to be inadequate in light of 
the extreme heterogeneity that is found from patient to patient, and many of them have 
failed to recognize a CSC population in specific breast tumor subtypes (Visvader and 
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Lindeman 2008). Therefore, other methods that rely on the functional characterization of 
CSCs have been adopted.  
Taking advantage of protocols that have been established for neural SCs, a population 
enriched in SCs was isolated from the normal mammary gland and propagated in vitro as 
non-adherent spheroids called mammospheres (Dontu, Abdallah et al. 2003). Briefly, 
mammospheres were shown to be: i) clonal in origin and able to self-renew, as they can 
form successive generations of spheroids upon dissociation and re-plating; ii) able to grow 
in anchorage independent conditions; iii) able to differentiate along the basal and luminal 
epithelial lineages and, in the presence of prolactin, generate acinar structures positive for 
β-casein. Furthermore, mammospheres were shown to contain cells that are slowly 
proliferating and endowed with higher self-renewal capacities than highly proliferating 
cells, and to be hierarchically organized according to each cell’s replicative potential 
(Cicalese, Bonizzi et al. 2009, Pece, Tosoni et al. 2010).  
Therefore, the mammosphere assay represents a useful tool to model self-renewal in vitro 
since it provides a measure of: i) the clonogenic and differentiating potential of a given 
population, and ii) its self-replating ability, as only SCs can be serially passaged. Indeed, 
mammosphere assays have been widely used to estimate SC and CSC contents in the 
mammary field. For example, mammospheres arising from primary human breast tumors 
are composed of cells that show a CD44+/ CD24- phenotype and are greatly enriched in 
tumor initiating cells, thus indicating that the mammosphere assay is indeed a good system 
to propagate cancer SCs (Ponti, Costa et al. 2005). Furthermore, as mentioned before, Pece 
and colleagues demonstrated that poorly differentiated (G3) breast cancers have higher 
mammosphere forming ability than well differentiated G1 tumors, as they possess higher 
content of CSCs (Pece, Tosoni et al. 2010).  
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This explains why the mammosphere assay has been so extensively used lately to study 
SC/CSC specific players and pathways, and how their manipulation impacts on their self-
renewal ability. This assay also represents a valuable tool to test therapeutics and predict 
biological response in tumors organized according to the CSC model. 
 
2.3 Cancer	  stem	  cell	  specific	  mechanisms	  
 
Up to now, we have described the CSCs as “caricatures” of the normal adult SCs, indeed 
many are the features that are shared between these two populations, and the normal SCs 
are thought to be the “cell of origin” of particular subtypes of cancers. 
As successful therapeutic strategies should aim to minimize their impact on normal SCs 
while eradicating the malignant regenerative clones, understanding the mechanisms 
inherent to CSCs that distinguish them from their normal counterparts is a key issue in 
cancer biology. To this end, the dissection of SC de-regulated cell processes in the 
presence of an activated oncogene (or a de-activated tumor suppressor) is fundamental.  
 
2.3.1 CSC	  specific	  pathways	  
 
Many pathways have been found to be essential regulators of self-renewal and proliferation 
in SCs and profoundly de-regulated in the oncogenic process. Among them, several ligand-
dependent signaling pathways involved in normal self-renewal and development, such as 
Wnt, Notch and Hedgehog have raised the interest of many research groups. On the other 
hand, genes which regulate the apopototic and DNA damage response pathways, such as 
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p53, p21, pTEN, and negative regulators of the SC state like TGF-β are also considered for 
their role in inhibiting SC self-renewal (Visvader and Lindeman 2008) (Figure 2-5).  
 
Figure 2-5: CSC specific signaling cascades: Notch, Wnt, PTEN, Hedgehog pathways are depicted. 
(Templeton, Miyamoto et al. 2014) ©Stem Cell Investigation. 
 
The Notch receptor family is part of signaling pathways involved in the regulation of the 
fate of cells in a variety of tissues and is fundamental in the development of the embryo. In 
the mammary gland, while Notch1 and 3 are expressed in luminal committed progenitors, 
Notch4 expression is higher in bipotent MaSCs and significantly down-regulated upon 
differentiation along the luminal and myoepithelial lineages (Liu, Dontu et al. 2005). 
Transgenic mice harboring a constitutively active Notch4 (MMTV-Int3) exhibited 
impaired mammary gland development and grew poorly differentiated adenocarcinomas 
(Uyttendaele, Marazzi et al. 1996). The same tumorigenic effects on the mammary gland 
were also observed for over-activation of both Notch1 and Notch3 (Hu, Dievart et al. 
2006). Furthermore, high levels of Notch1 and Notch3 were correlated with poor prognosis 
in breast cancer patients (Reedijk, Odorcic et al. 2005). All together these findings 
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highlight that abnormal Notch expression is linked to breast carcinogenesis through the 
deregulation of normal mammary stem cell self-renewal. 
Wnt signaling is another very well studied pathway for its involvement in SCs, 
development and tumorigenesis. The canonical Wnt pathway has its main downstream 
effect in the stabilization of β-catenin in the nucleus, which, together with the transcription 
co-factors TCF/LEF, initiates the transcription of target genes essential for normal 
mammary gland development. Notably, it was shown that the adult mammary gland 
contain a Wnt-responsive cell population that is enriched for stem cells and that Wnt 
constitutive signaling expands this cell population (Zeng and Nusse 2010). The role of Wnt 
in tumorigenesis is being also widely studied in many different cancers. As regards breast 
carcinogenesis, the MMTV-Wnt1 mouse model develops tumors with 50% penetrance and 
6 months latency (Li, Hively et al. 2000) and presents increased number of MaSCs, which 
were shown to be radio-resistant (Diehn, Cho et al. 2009). Furthermore, it was reported 
that the active form of β-catenin is over-expressed in breast cancer (Visvader and 
Lindeman 2008). 
All together the above examples confirm that an aberrant regulation of SC self-renewal 
triggers tumor development and progression. 
A way to avoid any potential toxicity to normal SCs, since the above-mentioned 
mechanisms are shared with them, is to target mutations that are active only in CSCs.  
There have been several attempts to apply this concept, mainly in hematopoietic 
malignancies. For example, deletion of the PI-3 kinase pathway regulator Pten, combined 
with targeting of the mTOR pathway by rapamycin, led to the selective elimination of 
LSCs without affecting the survival and the function of normal HSC, which were instead 
impaired upon depletion of Pten alone (Yilmaz, Valdez et al. 2006). In addition, therapies 
against surface markers exclusively exhibited by CSCs have been tried. Monoclonal 
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antibodies against CD44, IL-3R, CD47 and the immunoglobulin mucin Tim-3 have been 
developed and utilized to specifically target LSCs in human AML (Chen, Huang et al. 
2013). Targeting CD44, in particular, might be a good candidate therapy also for CSCs in 
solid cancers, as normal HSCs do not seem to use this molecule for their adhesion 
signaling (Jin, Hope et al. 2006).  
These observations suggest that a CSC based anticancer approach should be selectively 
targeting mechanisms of tumor propagation.  
 
2.3.2 P53	  role	  in	  CSCs	  
 
The tumor suppressor p53 is unequivocally one of the most crucial genes for cancer.  
Inactivation of its function is a very common event as it happens in more than 50% of all 
sporadic human tumors (Vousden and Prives 2009). During tumor development, a 
mutational event in the p53 gene is usually followed by loss of heterozygosity, which 
results in the complete loss of p53 function. Depending on the tumor type, p53 deficiency 
is involved in the initiation or progression of cancer and it is frequently associated with 
higher tumor aggressiveness (Miller, Smeds et al. 2005). In breast cancer, inactivation of 
p53 is present in around 80% of basal-like tumors, the most malignant and undifferentiated 
subtype (Cancer Genome Atlas 2012, Curtis, Shah et al. 2012), and several reports indicate 
that p53 loss is correlated with the acquisition of a SC transcriptional signature and SC-like 
phenotypes (Spike and Wahl 2011).  
The tumor suppressive function of p53 has been historically associated with its role in 
hindering the cell cycle, through induction of apoptosis and senescence in response to a 
plethora of diverse stresses: DNA damage, hyperproliferative signals, oxidative stress, 
hypoxia, just to mention a few. In the presence of these stimuli, p53 is stabilized by the 
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displacement from the E3-ubiquitin ligases that control its levels (Mdm2, mainly, and 
Mdm4) and consequently activated. However, more recently, p53 tumor suppressive role 
has been involved in many additional biological processes including SC-related functions 
(Vousden and Prives 2009) (Figure 2-6).  
 
 
Figure 2-6: Pleiotropic nature of p53 functions in a) somatic and b) SC compartments. (Bonizzi, 
Cicalese et al. 2012) ©TRENDS in Molecular Medicine 
 
P53, in fact, acts as a negative regulator of SC self-renewal at multiple levels. First of all, 
p53 maintains the quiescent pool of HSCs, preventing their exhaustion (Liu, Elf et al. 
2009) and its loss has been shown to induce severe impairment of self-renewal in 
hematopoietic progenitors, thus facilitating AML development (Zhao, Zuber et al. 2010). 
Furthermore, a key evidence supporting this role comes from the fact that p53 can inhibit 
reprogramming of differentiated somatic cells into induced pluripotent stem cells (iPSCs) 
(Hong, Takahashi et al. 2009). This is achieved both through p21-dependent cell cycle 
arrest and through trans-activation of miR-34a and miR-145, which negatively regulate 
essential pluripotency genes (Bieging, Mello et al. 2014). Conversely, a recent study in 
liver cancer has shown that p53 loss contributes to tumorigenesis by favoring de-
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differentiation of adult hepatocytes into early progenitor cells, endowed with CSCs 
potential to give rise to hepatocellular carcinomas (Tschaharganeh, Xue et al. 2014).  
Indeed, it is becoming more and more evident that certain tumor cells have the ability to 
reversibly transit among states with different competence in tumor sustainment, a 
biological property that goes under the definition of cancer plasticity. In breast cancer, for 
example, tumor cells can switch from epithelial to mesenchymal functional specializations, 
a process called epithelial to mesenchymal transition (EMT) which also occurs 
physiologically during organism development or wound healing, with the cells in the 
mesenchymal state appearing more capable of forming tumors (Mani, Guo et al. 2008).  
In details, the expression of a certain set of genes in epithelial cells promotes the 
disassembling of cell-to-cell junctions and endows them with a mesenchymal, migratory 
phenotype. Many transcription factors promote EMT, among them the Snail, Twist and 
Zeb families, and, importantly, their activity seems to be orchestrated by p53. For example, 
p53 indirectly inhibits the expression of Snail, Zeb1 and Bmi1 by trans activating 
regulatory miRNAs (Bieging, Mello et al. 2014). In the work of Mani and colleagues, the 
induction of EMT in immortalized human mammary epithelial cells by the ectopic 
expression of snail or twist leads to the formation of cells with CSC characteristics. Also, 
markers of EMT were found to be expressed by CD24-/CD44+ cells in human breast 
cancer (Mani, Guo et al. 2008). Thus, there is increasing evidence that more differentiated 
cells can undergo phenotypical changes that allow them to acquire CSC specific features. 
This process has the direct consequence of expanding the pool of CSC. 
 
Furthermore, a role for p53 in the regulation of the balance between SC symmetric and 
asymmetric division has been demonstrated. The mode of division of SCs is a key issue in 
SC biology and one of the critical features that allows them to sustain tissue homeostasis 
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and tissue specialization. Indeed, unlike more specialized cells, SCs have the ability to 
undergo both symmetric and asymmetric cell division, generating daughter cells that are 
either both endowed with the same properties of the mother or that are distinct in terms of 
their cell-fate. Under physiological conditions, the ratio between symmetric and 
asymmetric division is tightly regulated in order to maintain the balance between SC self-
renewal and differentiation. When the choice between symmetry and asymmetry is 
uncontrolled, the consequences for development and disease are huge, inducing disruption 
of organ morphogenesis or leading to malignant transformation. This was demonstrated for 
the first time in Drosophila through genetic screens that showed how the mutagenesis of 
critical players of the asymmetric cell division (ACD), such as Brat, triggered the 
formation of brain tumors upon transplantation (Betschinger, Mechtler et al. 2006). 
Our group showed that, in a murine model of breast cancer driven by the mutated form of 
the erbB2 gene, the increased frequency of symmetric divisions in CSCs, compared to their 
normal counterparts, is the underlying mechanism of CSC expansion, as seen by sphere 
forming assay and in vivo sustainment of the cancer clone. In this work, Cicalese and 
colleagues reported that the switch towards symmetric self-renewal was instructed, at the 
molecular level, by p53 loss; indeed, by restoring p53 function, asymmetric cell division in 
the CSCs was re-established, leading to a reduced frequency of tumor formation (Cicalese, 
Bonizzi et al. 2009). Other reports confirmed the role of p53 (and its downstream effectors) 
in regulating asymmetry in neural progenitors (Sugiarto, Persson et al. 2011) and in colon 
cancer cultures, through the asymmetric segregation of miR-34a, a p53 target micro-RNA 
(miRNA), whose role is to promote differentiation in one of the daughter cells (Bu, Chen 
et al. 2013). Therefore, it appears clear that increased symmetric renewal could be the basis 
of the differentiation arrest and clone expansion that are inherent to cancer progression. 
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All together these findings highlight the importance of a negative regulation of “stemness” 
as part of the tumor suppressive program orchestrated by p53. Indeed the expansion of the 
CSC compartment could be one of the driving forces for tumor development and 
maintenance.  Nevertheless, the downstream pathways and effectors that are crucial for the 
execution of this program remain largely unknown.   
 
2.4 Myc	  at	  the	  crossroad	  of	  SC	  biology	  and	  cancer	  
 
The product of the oncogene c-myc belongs to Myc family of transcription factors, which 
also includes N-Myc and L-Myc. This family contains basic helix-loop-helix (bHLHZ) 
domains that mediate the interaction with target DNA. Endowed with a very pleiotropic 
nature, Myc coordinates an impressive number of biological functions due to its ability to 
act as a i) transcriptional activator through its hetero-dimerization with Max, ii) 
transcriptional repressor, through its interaction with Miz1, and iii) chromatin remodeler 
(Amati, Frank et al. 2001). Myc is at the center of an intricate network of growth-
promoting signals and it is activated downstream of many different ligand-dependent 
stimuli. Its expression in normal cells is highly regulated by a number of mechanisms at 
the transcriptional and post-transcriptional level (Dang 2012). The transcriptional program 
instructed by Myc touches many biological processes, such as cell proliferation, DNA 
replication, metabolic shifts, stemness, differentiation, and apoptosis, which, once de-
regulated, constitute many of the “hallmarks of cancer” (Hanahan and Weinberg 2011). 
Therefore, it is not surprising that Myc aberrant activity is often linked to malignant 
transformation. 
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2.4.1 Myc	  in	  the	  maintenance	  of	  SC	  self-­‐renewal	  
 
Among its functions, the role of Myc in SC biology is one of the most intense areas of 
study, as it constitutes the paradigm for the multiple aspects of its biological activity.  
Myc plays a critical role both at the stage of organism development and in adult tissues by 
regulating the cell fate of stem and progenitor cells. In Drosophila neuroblasts, cell cycle 
exit and subsequent differentiation of one of the daughter cells generated by ACD is 
mediated by the Brat gene, that exerts this function by negatively regulating Drosophila 
Myc (dMyc) (Betschinger, Mechtler et al. 2006).  
Similar observations have also been made in mammalian SCs. Myc is required for 
embryogenesis as knock-out of both c-Myc and N-Myc results in early lethality of mice 
embryos, thus proving that Myc is essential in ESC pluripotency and self-renewal 
(Varlakhanova, Cotterman et al. 2010). Accordingly, it has been demonstrated that ectopic 
expression of Myc inhibits the differentiation of ESCs; indeed, constitutive expression of a 
mutant form of Myc (T58A, which is not degraded by Fbw7 ubiquitin ligase) maintains 
ESC self-renewal and pluripotency even in the absence of leukemia inhibitory factor (LIF) 
in the growing media. In contrast, inhibition of Myc induces ESC differentiation 
(Cartwright, McLean et al. 2005). Furthermore, it is possible to recognize a distinct 
signature of Myc-dependent targets within the set of genes expressed in ESCs (Kim, Chu 
et al. 2008); notably, this set of genes was found to correlate with human cancer signatures 
(Kim, Woo et al. 2010) (Figure 2-7). 
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Figure 2-7: Myc-dependent network is a feature of ESCs and is highly activated in cancer. (Kim, Woo 
et al. 2010) Copyright © 2010 Elsevier Inc. All rights reserved. 
 
These data are coherent with the fact that Myc has a fundamental role in somatic cell 
reprogramming together with other three transcription factors (TFs): Oct4, Sox2, Klf4 (all 
together under the name of OSKM) (Takahashi and Yamanaka 2006). Although several 
studies demonstrated that Myc is not absolutely required for iPSC generation, its presence 
increases the speed and the efficiency of the process. Indeed, for specific cell types 
harboring high levels of Myc expression (like neural progenitors and keratinocytes), Myc 
is completely dispensable from the “reprogramming cocktail” (Singh and Dalton 2009). It 
seems plausible that Myc aids reprogramming by maintaining the cells in a highly 
proliferative state, which is a characteristic of pluripotent cells (Singh and Dalton 2009). In 
addition, given that Myc-binding to promoter regions of target genes is associated with 
open chromatin marks and is correlated with the amount of RNA polymerase recruited, 
recent reports suggest that OSK factors might act as “pioneers” to enable binding of Myc 
to regions of inaccessible chromatin. At the same time, Myc might facilitate the initial 
binding of OSK factors to chromatin through a cooperative mechanism (Soufi, Donahue et 
al. 2012, Buganim, Faddah et al. 2013).  
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The role that Myc holds in ESC pluripotency and its effects on differentiation is 
maintained in adult SCs. The study of Myc in tissue SCs has revealed, however, a more 
blurred situation: depending on the cell context, Myc can enhance self-renewal and inhibit 
differentiation, or promote terminal commitment. For example, in the skin, ectopic 
expression of Myc, under the control of the SC-specific promoter K14, induces long-term 
depletion of SCs, due to increased rate of proliferation and accumulation of differentiated 
cells in the adjacent layers of the epidermis (Watt, Frye et al. 2008). In the hematopoietic 
system, depletion of Myc impedes the mobilization of HSCs from their niche causing their 
accumulation, an event that leads to concomitant loss of all the differentiated progeny. 
Interestingly, the depletion of Myc does not affect the dormant pool of HSCs, indicating 
that the dependence of cells on Myc varies according to the cell-cycle status (Wilson, 
Murphy et al. 2004, Laurenti, Varnum-Finney et al. 2008). As far as more differentiated 
progenitors are concerned, Myc overexpression confers on them higher self-renewal 
capacities; this is what happens, for example, in late-stage neural SCs, where this effect of 
Myc is exerted by its co-regulator Miz-1 (Kerosuo, Piltti et al. 2008). In line with this, it 
was reported that enforced Myc expression in an immortalized human breast line drives 
EMT through the induction of the GSK-3β/Snail signaling pathway (Cho, Cho et al. 2010), 
thus remarking the importance of Myc in reprogramming cell fates also in adult tissues.  
The essential role of Myc in SCs was also characterized in the mammary gland. 
Conditional deletion of Myc in the basal compartment impairs SC self-renewal, as assessed 
by limiting dilution transplantation and mammosphere assays, and consequently disrupts 
differentiation into the luminal and myoepithelial lineages (Moumen, Chiche et al. 2012). 
Taken together these data highlight the importance of Myc in cell fate determination as 
well as the strong dependency of its function on the cellular context. Therefore, it clearly 
emerges that a careful regulation of Myc levels is needed by each cell type to properly 
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function, according to its replicative potential and grade of specialization; however, 
additional studies are required to provide a richer mechanistic understanding. 
 
2.4.2 Upstream	  of	  Myc	  
 
The regulation of Myc expression is a very complex area of study; indeed, many pathways 
and TFs converge into Myc signaling. The transcriptional regulation of the c-myc promoter 
itself is extremely challenging, with a lot of redundancy, many feedback loops, and several 
cross-­‐‑regulatory circuits involved (Wierstra and Alves 2008). Indeed, besides the 
regulation acted by a number of TFs, it has been proposed that a number of unconventional 
DNA-binding proteins recognizing non–B DNAs structures, including single-stranded 
bubbles, G-quadruplexes, and Z-DNA, also regulate c-myc (Levens 2010). 
As mentioned, numerous are the TFs that have the ability to bind and regulate the c-myc 
promoter and subsequently drive a plethora of different cell responses. Few examples 
include: TCF, whose role downstream of the Wnt pathway is important for embryonic 
development, proliferation and adult SC self-renewal (Dang 2012); TGF-β, one of the most 
important cytostatic stimulator that represses the c-­‐‑myc promoter through its downstream 
effectors Smad3/4; STAT3, a mediator of cell proliferation and survival that participates in 
cellular transformation and tumorigenesis; the NF-­‐‑κB/Rel family, that orchestrates 
inflammatory and immune responses and regulates cell proliferation, survival, and 
differentiation; AP-1 with c-Fos/Jun, E2F. Furthermore, Notch, Hedgehog and many other 
cell fate regulators pathways converge into Myc regulation (Wierstra and Alves 2008). 
Myc itself regulates its own expression at the transcriptional level in a concentration 
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dependent manner; this represents a fundamental homeostatic mechanism of protection for 
normal cells that is lost in many transformed cell lines (Wierstra and Alves 2008).  
A fine control over Myc levels takes also place at the post-transcriptional level. For 
example, the Ras-driven pathway induces phosphorylation on Ser62, stabilizing the Myc 
protein, and at the same time inhibits the phosphorylation, by GSK-3β, of the Thr58 
residue. This last modification is recognized by the Fbw7 E3 ubiquitin ligase that binds 
Myc for proteasomal degradation (Welcker and Clurman 2008). Furthermore, other 
ubiquitin ligases contribute to the regulation of Myc half-life; among them, the murine Brat 
orthologue Trim32 is asymmetrically distributed during the ACD of neural SCs and 
becomes up-regulated during neuronal differentiation, thus enhancing the ubiquitin-
mediated degradation of Myc in the differentiating cells (Schwamborn, Berezikov et al. 
2009, Izumi and Kaneko 2014). The ubiquitin-proteasome system (UPS) is not the only 
mechanism involved as many miRNAs, such as let-7, miR-34, and miR45, are known to 
target and degrade Myc transcripts (Dang 2012).  
Therefore, it emerges that vigilant control of Myc levels is crucial for normal cells, as 
disruption of any of the regulatory mechanisms leads to pre-transformed phenotypes. 
Notably, most of the regulators of Myc activity are likely involved in the CSC specific 
mechanisms that we have described earlier. 
Among the upstream regulator of Myc there is also p53: simultaneous inactivation of p53 
and PTEN in neural SCs is accompanied by over-expression of Myc and its associated 
signature, and results in increased self-renewal and the promotion of an undifferentiated 
state that is one of the underlying traits of human glioblastoma (GBM) (Zheng, Ying et al. 
2008). These findings are concordant with observations that describe a role for p53 in the 
repression of Myc expression and which is achieved by direct binding of p53 to the Myc 
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promoter (Ho, Ma et al. 2005), or to distal regulatory elements (Li, He et al. 2012), or by 
means of intermediate regulatory miRNAs (Sachdeva, Zhu et al. 2009). 
 
2.4.3 Myc	  activation	  in	  cancer	  
 
Our brief overview emphasizes how the de-regulation of Myc in a permissive epigenetic 
and genetic cellular context allows overcoming the checkpoint mechanisms and leads to 
the establishment, in the cell, of many of the “hallmarks of cancer”. A de-regulated Myc 
drives proliferation, high rate of DNA replication and transcription, altered cellular 
metabolism, increased protein synthesis, changes in the tissue microenvironment, supports 
stemness, and blocks senescence and differentiation. Each of these processes is associated 
with tumor growth and maintenance (Gabay, Li et al. 2014). The most common events that 
could results in Myc de-regulation are: genetic amplification, chromosomal translocation 
and constitutive activation/repression of the upstream regulatory signaling.  
In breast cancer, Myc genetic amplification takes place in 22% of the cases reported in the 
Cancer Genome Atlas (TCGA) dataset (Cancer Genome Atlas 2012), while chromosomal 
translocation involving the myc locus has not been reported in breast cancer. Genetic 
amplification has been associated with higher risk of relapse and death by invasive 
metastasis and it seems to be an event correlated with other genetic predispositions: indeed, 
Myc amplification is found in 53% of tumors harboring Brca1 mutation (Xu, Chen et al. 
2010).  
Beside genetic amplification, the frequency of patients showing high levels of Myc, most 
likely due to the disruption of upstream regulatory mechanisms, is very high, but variable 
depending on the cancer subtype. Early studies on small cohorts of patients reported that 
Myc over-expression is associated with basal-like breast tumors (Sotiriou, Neo et al. 2003). 
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The basal-like breast cancer is the most challenging of the breast cancer subtypes: it 
histologically derives from the basal compartment of the normal mammary epithelia (the 
one that putatively contains SCs). It is negative for the expression of estrogen, 
progesterone and Her2 receptors; it shows an early stage onset and a strong tendency to 
metastasize, and currently there are no therapeutic options for targeted pharmacological 
treatment. In line with the data of over-expression, a Myc-dependent gene signature, which 
is included in a larger set of ESC specific genes, was reported to positively correlate with 
basal-like or ER negative breast tumors, with shorter interval to metastasis, and, generally, 
with poorer prognosis (Kim, Woo et al. 2010).  
Therefore, like for the loss of p53, a role in the progression and sustainment of the less 
well-differentiated tumors, through the maintenance of a SC-like state, also emerges for 
Myc. In line with this, in Burkitt’s lymphomas and hepatocellular carcinomas, it has been 
shown that inhibition of Myc causes tumor regression by restoring the physiological 
program of cellular differentiation (Karlsson, Giuriato et al. 2003, Shachaf, Kopelman et 
al. 2004), thus strengthening the concept that de-regulation of Myc favors tumor 
progression by enhancing self-renewal and inhibiting differentiation. Considering the role 
of both Myc and p53 in somatic cell reprogramming, it is plausible to hypothesize that they 
could be involved in tumor progression by promoting the formation of cancer cells that 
retain developmental plasticity. 
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3 Materials	  and	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3.1 Animal	  Manipulation	  
3.1.1 Animal	  Models	  
 
MMTV-ErbB2 transgenic mice were in the FVB background (Muller, Sinn et al. 1988). 
P53-/- and p53+/- mice were in the C57/BL6J background (back-crossed in our group 
starting from a 129sv background). Rosa26-MycER transgenic mice were in C57/BL6J 
background (Murphy, Junttila et al. 2008), kindly provided by B. Amati’s group 
(Department of Experimental Oncology, European Institute of Oncology). As controls we 
used mice of the same strain, negative for the presence of the transgene (called wild type 
(WT) Rosa26-MycER). Transgenic mice expressing the green fluorescent protein (GFP) 
(Hadjantonakis, Gertsenstein et al. 1998), employed for serial transplantation experiments 
were in FVB background. All the experiments with WT mammospheres were carried out 
in samples derived from FVB WT mice. 
 
3.1.2 4-­‐Hydroxy-­‐Tamoxifen	  (4-­‐OHT)	  administration	  in	  vivo	  
 
WT C57/BL6J mice were tested for tolerability of long-term administration of 4-OHT and 
its effects on the mammary gland tissue. 3 week-old and 8 week-old mice were fed with 
Tamoxifen- containing diet or standard diet for 14 days, then they were sacrificed and their 
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mammary glands digested and analyzed at FACS for the expression of epithelial SC 
markers. Tamoxifen- containing food was purchased from Harlan (TD. 130859) and, 
according to manufacturer instructions, provided ~40 mg tamoxifen per kg body weight 
per day assuming 20-25 g body weight and 3-4 g intake.  
 
3.1.3 Nutlin-­‐3	  treatment	  in	  vivo	  
   
Nutlin-3 for in vivo studies was purchased from Sigma Aldrich. FVB mice transplanted 
with tumor cells infected with either empty vector or MycER vector were treated with 
Nutlin-3 (20 mg/kg body weight) or DMSO (both diluted 1:1 with PBS) for two weeks by 
intra-peritoneal (IP) injection once every two days. Mice were sacrificed immediately after 
treatment to evaluate the effect o Nutlin-3 on tumor growth. 
 
3.1.4 Transplantation	  Experiments	  
 
For mammary gland reconstitution assays, the sample material to be injected (dissociated 
mammospheres, PKHneg cell subset) was collected; cells were counted and resuspended in 
PBS at the appropriate cell density in 25 µL of final volume per injection. 3 week-old 
female FVB mice were anaesthetized with 2.5% Avertin in PBS (100% avertin: 10 g of 
tribromoethanol, Sigma, in 10 ml of tertamyl alcohol, Sigma) and the fat-pad of their 
inguinal mammary gland was depleted of the endogenous epithelium. At 3 weeks of age 
the mammary epithelial tree has not undergone the puberty-driven development that results 
in the penetration of the fat pad, and can be easily removed by surgical cut of the area 
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spanning from the nipple to the lymph node, leaving the fat-pad clear for the injection of 
exogenous cells.  
For the injection of tumor cells (infected in vitro with MycER or the corresponding empty 
vector) we used 8 week-old virgin mice and no clearing of the fat pad was performed. 
200,000 cells were injected orthotopically in one inguinal mammary gland per mouse and 
almost 100% of mice developed secondary tumors with a latency of 40-50 days. 
 
3.1.5 Carmine	  Alum	  Whole	  Mount	  staining	  
 
Transplanted mammary glands were stretched out onto slides and fixed overnight in 4% 
formaldehyde. Slides were washed twice in distilled water for 10 minutes and then stained 
overnight at room temperature with Carmine Alum solution (0.2% carmine, 0.5% 
aluminium potassium sulfate in water, Sigma). De-staining was performed in 70% ethanol 
for 30 minutes, followed by two 30 minutes washes in 95% and 100% ethanol. Finally, 
samples were soaked in a 1:2 solution of benzylalcohol/benzylbenzoate (Sigma) until the 
fat pad color clarified. For immunohistochemistry (IHC) analyses, glands were re-hydrated 
through alcohol gradient (100% - 95% - 70%) and stored for paraffin embedding.  
 
3.1.6 Evaluation	  of	  positive	  transplants	  and	  statistical	  analysis	  
 
For the evaluation of positive outgrowths, the fat pads were collected ~12 weeks after 
transplantation, stained with Carmine Alum and analyzed as previously reported (DeOme, 
Faulkin et al. 1959). Briefly, fat pads were scored as negative for outgrowths if no 
epithelial structures could be observed. In some cases, endogenous epithelial re-growth 
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was scored. This is defined as an epithelial ductal network in which the majority of ductal 
branching had the same direction and had grown in from the cut edge of the cleared fat 
pad; in those cases the transplants were excluded from the statistics. The outgrowths were 
scored as positive if the ductal branching had originated from a central region of the 
cleared fad pad and the directionality of the ductal branching was variable in different parts 
of the fat pad. The presence of TEBs in the outgrowths was also a hallmark of exogenous 
epithelial growth.  
Limiting dilution analysis was performed using the Extreme Limiting Dilution Analysis 
(ELDA) web tool (http://bioinf.wehi.edu.au/software/elda/) (Hu and Smyth 2009). ELDA 
computes a 95% confidence interval for the active cell frequency in each population group. 
One-sided confidence intervals are developed for stem cell frequency for subpopulations 
that produce 0% or 100% positive outgrowths. Furthermore, ELDA implements a 
likelihood ratio test for the acceptance of the single-hit hypothesis, which guarantees 
greater power and much improved performance in small samples as compared to a t-
statistic approach. ELDA also computes an overall test for differences between the 
population groups, analogous to a one-way ANOVA test.  
 
3.1.7 Preparation	  of	  paraffin	  sections	  	  
 
For the preparation of paraffin-embedded sections: hydrated whole- mounted tissues were 
sequentially treated for 1 hour at room temperature with 70%, 80%, 95% ethanol, three 
times with 100% ethanol, twice with xylene and twice for two hours at 58°C with paraffin. 
The specimens were then embedded in paraffin and sectioned with a microtome at 5µm 
thickness. Slides were stained with haematoxylin-eosin for histological analysis or stained 
by IHC.  
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3.1.8 Immunohistochemistry	  
 
Paraffin sections were de-paraffinized with histolemon (Carlo Erba) for 10 minutes twice 
and hydrated through graded alcohol series (100%, 95%, 70% ethanol and water) for 5 
minutes each. Antigen unmasking was performed in boiling citrate buffer (10mM sodium 
citrate, 0.05% tween20, pH 6.0) for 30 to 50 minutes, followed by incubation with 3% 
hydrogen peroxide in distilled water for 10 minutes at room temperature. Slides were 
subsequently pre-incubated with an antibody mixture (2% BSA, 5% FBS, 0.02% Tween20 
in TBS) for 20 minutes at room temperature and then stained with primary antibody 
overnight at 4°C. After two washes with TBS slides were incubated with a secondary 
antibody (DAKO Envision system HRP rabbit or mouse) for 30 minutes at room 
temperature and washed twice again in TBS. The sections were subsequently incubated in 
peroxidase substrate solution (DAB DAKO) for 2 to 10 minutes, rinsed in water, 
counterstained with hematoxylin for 30 seconds, dehydrated through graded alcohol series 
(water and 70%, 95%, 100% ethanol) for 5 minutes each and ultimately mounted with 
Eukitt (Kindler GmbH). All primary antibodies and their relative concentrations used in 
this study are listed in Table 3-1.  
 
Antibody Clone Company Concentration 
Rabbit anti-Cytokeratin 14 (K14)  Covance; PRB-155P 1:500 
Mouse anti-Cytokeratin 18 (K18) Ks18.04 Progen; 61424 1:20 
Rabbit anti-KI67  Thermo Scientific; RM-9106-S 1:200 
Rabbit anti-βcasein  Santa Cruz Biotech.; sc30042 1:500 
Rabbit anti-GFP  Abcam; ab6556-25 1:500 
Table 3-1: List of antibodies and conditions used for IHC analysis. 
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A subset of samples was examined for detailed histopathological analysis. To assess the 
extent of the mammary epithelium in each examined sample, the area (µm2) occupied by 
mammary epithelium and the % Area = area occupied by epithelium/total area of field at 
100x * 100) were evaluated in hematoxylin-eosin (HE) stained sections using the ImageJ 
1.47v analysis program (imagej.nih.gov/ij/) in 4 100x microscopic fields selected in the 
areas with the highest amount of mammary epithelium (hot spots).  
To assess the extent of the proliferative activity, the number of Ki67-positive and Ki67- 
negative cells were counted using the ImageJ analysis program in 400x microscopic fields 
centered on mammary epithelial structures. The Ki67 index was then calculated as: nr. of 
positive cells divided by nr. of total cells.  
  
3.2 Cell	  culture	  
3.2.1 Isolation	  of	  mouse	  mammary	  epithelial	  cells	  
 
The inguinal and axillar normal mammary glands were collected from 6-10 week-old 
virgin WT, Rosa26-MycER transgenic heterozygous mice, or p53-/- and p53+/- mice. 
Tumors derived from MMTV-ErbB2 transgenic mice were collected at the time of their 
appearance (tumor latency: 12 to 16 weeks after birth). Mammary tissues were 
mechanically dissected into small pieces with scissors, and enzymatically digested with the 
following digestion mixture: Dulbecco’s modified Eagle’s medium (DMEM, 
BioWhittaker), 2 mM glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin, 
supplemented with 200 U/ml collagenase (Sigma) and 100 U/ml hyaluronidase (Sigma) on 
rotating wheel for 2-3 hours at 37°C in a humid atmosphere containing 5% CO2. When the 
digestion was complete, the cell suspensions were centrifuged at 600 rpm for 5 minutes 
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and then resuspendend in PBS and filtered through 100, 70 and 40 µm cell strainers to 
eliminate cell aggregates.	  Red blood cells were lysed with ACK lysis buffer (Lonza) for 2 
minutes in ice. Cell suspension depleted of red blood cells was washed in cold PBS and 
plated to obtain mammospheres, stained with the PKH26 fluorescent dye or used for 
growth assays.  
 
3.2.2 FACS	  analysis	  of	  epithelial	  cell	  sub-­‐populations	  
 
Single cells isolated from the mammary tissue were mixed with digested organoids. 
Organoids were derived from the collection of aggregates that did not pass through each of 
the cell strainer used. This material was further digested with trypsin/EDTA (Lonza), 
dispase (5U/mL, Stem Cell Technologies) and DNase (1mg/ml, Stem Cell Technologies). 
Inactivation of the enzymes was performed with cold PBS supplemented with 2% FBS. 
The cell suspension of single cells and digested organoids was blocked in BSA 10% and 
then stained for mammary stem cell markers as listed below:  
- Lineage cocktail (Lin-): anti-CD45 (eBioscience, clone RA3-6B2); ant-Ter119 
(eBioscience, clone Ter119); anti-CD31 (eBioscience, clone 390); all PE-Cy7 
conjugated (1:300) 
- Anti-CD49f (eBioscience, clone GoH3) eFluor®450 conjugated (1:100) 
- Anti-CD61 (eBioscience, clone 2C9.C3) PE conjugated (1:40) 
- Anti-EpCAm (eBioscience, clone G8.8) APC conjugated (1:200). 
In selected experiments, Lin- cells were isolated by column-based negative selection that 
was performed through the EasySep™ Mouse Epithelial Cell Enrichment Kit (Stem Cell 
Technologies). 
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Samples were acquired at FACS Canto II (BD bioscience) and analyzed with FlowJo 9.3-2 
analysis software. 
 
3.2.3 Mammosphere	  culture	  
 
Primary mammary cells were plated onto ultralow attachment 6-well plates (Falcon) at a 
density of 200,000 viable cell/mL (to obtain primary mammospheres) in a serum-free 
mammary epithelial basal medium (MEBM, BioWhittaker), supplemented with 2 mM 
glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin, 5 µg/ml insulin, 0.5 µg/ml 
hydrocortisone, 2% B27 (Invitrogen), 20 ng/ml EGF and βFGF (Peprotech), and 4 µg/ml 
heparin (Sigma) and cultured at 37°C in 5% CO2. In these conditions mammary epithelial 
cells grow as clonal colonies called mammospheres (Dontu, Abdallah et al. 2003) that 
reach their maximum size in 5-6 days. After 7 days of culture, primary mammospheres 
(obtained from freshly isolated mammary cells) were dissociated mechanically using a 
Gilson® pipette with filtered tips and re-plated to obtain secondary mammospheres at a 
density of 20,000 cells/ml in 6-well low-adhesion plates. The same procedure was repeated 
at each passage.  
 
3.2.4 Mammosphere	  growth	  curves	  
 
For the modelling of mammosphere growth curves, primary mammospheres were 
dissociated mechanically and re-plated (at 20,000 cells/ml) to obtain secondary 
mammospheres in 6-well low-adhesion plates coated with poly-HEMA (Sigma). After 7 
days, the newly formed mammospheres were counted, collected and manually dissociated 
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by pipetting. At each passage, the number of retrieved mammospheres reflects the number 
of mammosphere initiating cells present in the original culture and the number of cells 
counted after dissociation allows for the evaluation of the number of cells per sphere that 
was formed. At each passage spheres were enumerated using digital image analysis 
(Imagej; object threshold 100 microns). Cumulative sphere and cell curves were calculated 
based on the ratio between plated spheres and obtained spheres and cells respectively. The 
number of plated spheres was derived from the total number of cells divided by the size of 
the mammospheres (nr. of cells / nr. of spheres) over the passages, under the assumption 
that the average mammosphere size in a culture does not change (Cicalese, Bonizzi et al. 
2009).  
The cumulative curves were plotted in a semi-logarithmic scale and they approximated an 
exponential curve, as expected for a cell population that grows or dies with a constant rate 
during the time. Growth rates (GRs) were evaluated as the slope of the trend-line of the 
exponential curves. The exponential regression of the data resulted in the value of the 
coefficients of determination (R2), which approximate 1 in each of the measured curve, 
thus indicating the goodness of the fitting model.  
 
3.2.5 PKH26	  assay	  
 
Primary Rosa26-MycER heterozygous and WT FVB mammary cells were resuspended at 
the concentration of 10 million cells/ml and stained for 5 minutes at room temperature by 
adding an equal volume of a PKH26 mix (1:2500 PKH-26 in PBS) (Sigma, PKH26- GL), 
light protected. The cells were then washed twice with culture medium and plated to obtain 
primary mammospheres. PKH-labeled mammospheres were collected after 7 days, and 
mechanically dissociated to obtain single cell suspension. After a filtering step with a 40 
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µm cell strainer cells were subjected to FACS sorting (Influx cell sorter equipped with a 
488 nm laser and with a band pass 575/26 nm optical filter for PKH26 fluorescence 
detection, BD). The gate for PKH negative population was selected according to the basal 
fluorescence of unstained cells and usually included the 25% of the live cells. The obtained 
PKHneg cells were cultured as mammospheres, plated for growth curves in presence or 
absence of 4-OHT or infected with lentiviral vectors and used in transplantation assays.  
 
3.2.6 Viral	  Infections	  
 
293-T and Phoenix-ECO packaging cells were cultured in DMEM supplemented with 10% 
FBS, 2 mM glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin. For lentiviral 
production 293-T cells were transfected with the calcium-phosphate procedure with a 
mixture of: 2,5 µg of pRSV (Rev), 5 µg of pMDL/pRRE (gag&pol), 3 µg of pENV (VSV-
G), and 10 µg of the lentiviral vector per plate. The same procedure was applied for 
transfection of Phoenix-ECO cells for retroviral production, which were transfected with: 5 
µg of PKAT2, 10 µg of retroviral vector. 62.5 µl of 2M CaCl2 were added to the DNA mix 
and brought to a total volume of 500 µl with water. The mix was added drop-wise to 500 µl 
of 2X HBS (HEPES buffered saline: 250mM HEPES pH 7.0, 250mM NaCl and 150mM 
Na2HPO4) by bubbling. After 15 minutes of incubation, the precipitate was distributed on 
70% confluent exponentially growing cells. The medium was replaced 12-16 hours later 
with mammosphere medium deprived of EGF and FGF. Viral supernatant was collected 24 
and 48 hours after and filtered through a 0.45 µm syringe-filter. Cells from dissociated 
primary mammospheres were resuspended in viral supernatants supplemented with growth 
factors and Polybrene (4 µg/mL) to a final concentration of 50,000 cell/ml and subjected to 
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two cycles of infection in suspension (overnight and 6h). Then, the cells were plated in 
fresh mammosphere medium to obtain secondary mammospheres.  
In selected experiments, the viral supernatant was concentrated by ultra-centrifugation for 
2h at 20,000 rpm at 4°C and the viral pellet obtained was resuspended in PBS at 1000X 
concentration. The viral stock was frozen (-80°C) and subsequently used to infect target 
cells in order to achieve high multiplicity of infection (MOI). The concentrated virus was 
employed for the infection of ErbB2 primary tumor cells in adhesion prior to the injection 
in congenic recipient mice. This alternative protocol allows for shorter culture periods 
compared to the mammosphere assay. 
In this study we employed the following viral vectors (Table 3-2): 
Lenti/Retro 
virus 
Backbone Insert Reference 
Lentivirus pWPI (Addgene #12254) MycER (Littlewood, Hancock et al. 1995) 
Lentivirus pTRIPZ Omomyc (Annibali, Whitfield et al. 2014) 
Retrovirus pBABE-puro (Addgene #1764) p53ER (Vater, Bartle et al. 1996) 
Table 3-2: List of viral vectors used in this study for stable transduction. 
	  
3.2.7 Cell	  Cycle	  Analysis	  
  
Clik-iT® Plus EdU kit for flow cytometry assay was purchased from Life Technologies. 
WT FVB and MMTV-ErbB2 mammospheres were labelled each day of the culture (from 
day 1 to day 5) for 1.5 hours and stained according to the manufacturer protocol. Cells 
were then fixed in ethanol 100% for 1 hour on ice and stained with propidum iodide (PI) 
solution (final 2.5µg/mL). Cells were then incubated with RNaseA (final 0.25mg/mL) at 
4°C for a minimum of 3 hours; then, the fluorescence signal was acquired at FACS Canto 
II (BD Bioscience) and files analyzed with the FlowJo 9.3-2 analysis software. 
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3.3 Expression	  Analyses	  
3.3.1 Quantitative	  PCR	  (qPCR)	  
 
Total RNA from mammospheres was isolated using Maxwell® 16 LEV simplyRNA cells 
kit (Promega), and reverse transcribed using random primers and ImProm-II™ reverse 
transcriptase (Promega), following manufacturer instructions. Real-time RT-PCR analyses 
were done in triplicate on the Applied Biosystems 7500 Fast Real-Time PCR System with 
the fast-SYBR Green PCR kit as instructed by the manufacturer (Applied Biosystems). 
The amount of each mRNA was normalized to the amount of GusB mRNA. The genes 
whose expression was under analysis in this study and the relative primers used for their 
amplification are listed in Table 3-3: 
 
Gene name Primer FW Primer RV 
GusB GTGGGCATTGTGCTACCTC ATTTTTGTCCCGGCGAAC 
c-Myc TTTGTCTATTTGGGGACAGTGTT CATCGTCGTGGCTGTCTG 
Ncl CATGGTGAAGCTCGCAAAG TCACTATCCTCTTCCACCTCCTT 
Odc1 GCTAAGTCGACCTTGTGAGGA  AGCTGCTCATGGTTCTCGAT  
Cad GATCATCATGGGGGAGAAAG  CCAAGCGTGAGAAGGAGAAC  
P21 TCCACAGCGATATCCAGACA GGACATCACCAGGATTGGAC 
Noxa CAGAGCTACCACCTGAGTTCG TACACTTTGTCTCCGATCTTCCT 
Bax AAGCTGAGCGAGTGTCTC CCTTGAGCACCAGTTTGC 
Table 3-3: List of genes and corresponding primers used for quantitative PCR analysis. 
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3.3.2 RNAseq	  and	  statistical	  analysis	  
 
A total amount of 300,000 cells were collected for each experimental group in biological 
triplicates and RNA was extracted as described in previous section. Libraries of template 
RNA molecules suitable for subsequent sequencing were prepared from 0.5 to 2 µg high 
quality input RNA using the Illumina® TruSeq® RNA Sample Preparation Kit v2 and 
following the manufacturer instructions. Sequencing was performed on Illumina HiSeq 
2000 sequencer, read length was 50 base pairs and sequencing depth was 35 million reads 
per sample. 
FastQ files were filtered discarding low quality reads (threshold on the quality score across 
all bases= 28). Alignment of the reads was performed with TopHat 2.0.8 and HTseq-count 
algorithm was used to annotate the reads to the Mm10 reference genome (NCBI reference 
sequence database annotation) and to calculate the per gene raw counts (http://www-
huber.embl.de/users/anders/HTSeq/doc/count.html) (Anders, Pyl et al. 2015). The read 
count was normalized via Loess normalization by the DESeq2 algorithm (Anders and 
Huber 2010). DESeq is an R package to analyze count data from high-throughput 
sequencing assays such as RNASeq to test for differential expression. In details, DESeq2 
calculates the total counts in each condition, and then it performs test statistics under the 
assumption of negative binomial distribution from which it calculates the pvalue. The 
statistics is then adjusted for benjamini-hochberg correction to calculate the False 
Discovery Rate (FDR or qvalue). The final step of the DESeq algorithm calculates the log2 
fold change between the two samples under comparison. Additionally a filter on the 
average low represented genes in terms of read count (cutoff = 10) is applied. The 
differentially expressed genes (DEGs) were obtained, as such, from pairwise confrontation 
of the selected sample and its relative control.  
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For the Gene Set Enrichment Analysis (GSEA, 
http://www.broadinstitute.org/gsea/index.jsp) we applied a filter on the q value setting the 
threshold as lower or equal to 0.01. The analysis was performed on GSEA v2.2.0 platform 
running the 5,618 ranked DEGs of the MycER list on the GSEA pre-ranked tool. As gene 
sets to overlap and calculate the normalized enrichment score (NES) we used the DEGs of 
selected experimental groups (ErbB2, p53-/- and ErbB2+Nutlin) subdivided in UP and 
DOWN regulated lists. P-values of GSEA were calculated by performing 1.000 random 
permutations of gene labels to create ES null distribution. 
Pathway and Gene Ontology analyses were performed by overlap of our gene set with the 
Molecular signature database (MSigDB v5.0) on the GSEA website 
(www.broadinstitute.org/gsea). 
 
3.3.3 Immunofluorescence	  
 
Cells from dissociated mammospheres were fixed in suspension with 2% formaldehyde for 
5 minutes at room temperature, washed three times in PBS and plated onto poly-lysinated 
coverslips, where they were let adhere O/N at 4°C. Cells were then permeabilized for 10 
minutes with 0.1% Triton-X100 in PBS at room temperature, washed three times in PBS 
and blocked with donkey serum (blocking solution) for 45 minutes. Staining with primary 
antibodies was performed in a humid chamber for 1 hour at room temperature and 
followed by three washes in PBS. Coverslips were then stained with secondary antibodies 
for 30 minutes at room temperature, washed three times in PBS, counterstained with DAPI 
and mounted with mowiol. Samples were analysed under an UpRight BX61 (Olympus) 
fluorescence microscope with a 60X/1.35 oil objective (Olympus). Acquired images were 
analyzed through MetaMorph® Microscopy Automation & Image Analysis Software 
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(Molecular Devices). In this work we used a rabbit monoclonal c-Myc antibody (1:250 in 
blocking solution, clone Y69, ab32072 Abcam) followed by an anti-rabbit A647-
conjugated antibody (1:400 in blocking solution).  
 
3.3.4 Western	  Blot	  Analysis	  
 
100,000 to 500,000 cells from dissociated mammosphere were collected, washed in PBS 
and lysed in 50 to 100 µl of RIPA buffer (Tris-HCl 50mM; NaCl 150mM; 1% NP-40; 
EDTA 1mM; 0.5% Sodium Deoxylcholate; 0.1% SDS) supplemented with protease 
inhibitors (Roche). Proteins were quantified with the use of the DC™ Protein Assay 
(Biorad) in a 96-well format and the absorbance was measured at 750 nm with the 
GloMax® 96 Microplate Luminometer (Promega). SDS-PAGE was performed using the 
NuPage® Novex® Gel System apparatus (Invitrogen) at a constant current of 120 V for 
approximately 2 hours. Samples were loaded on precast gels Nupage Novex 4-12% Bis-
Tris (Invitrogen) and the 1X NuPAGE® MOPS SDS was used as running buffer 
(Invitrogen). Following SDS-PAGE electrophoresis, proteins were transferred to 
nitrocellulose membranes (Protan; Schleicher & Schuell) by electroblotting for 1.5 hours at 
100 V and then were stained with Ponceau S to verify the efficiency of the transfer. 
Membranes were blocked for 1 hour in blocking solution: 10% low fat milk in TBS-T (Tris 
Buffered Saline, 0.1% Tween 20) for all the antibodies used except for anti-phospho-S15 
p53, which was in 5% BSA (Bovine serum albumin). The detailed conditions used for each 
antibody employed in this study are listed in Table 3-4: 
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Antibody Clone Company Concentration Antibody Mix 
Mouse anti-Vinculin  Sigma 1:10,000 1% milk in TBS-T 
Rabbit anti-c-Myc  
Cell Signaling 
cat.nr. 9402 
1:500 1% milk in TBS-T 
Mouse anti-p53 AI25 In house 1:5 1% milk in TBS-T 
Rabbit anti-
phosphoS15 p53 
 
Cell Signaling 
cat.nr. 9284 
1:500 1% BSA in TBS-T 
Mouse anti-p21 F-5 
Santa Cruz 
Biotechnology 
cat.nr. sc6246 
1:500 1% milk in TBS-T 
Table 3-4: List of the antibodies used for western blot analysis and relative conditions. 
 
The membranes were washed three times in TBS-T (10 minutes each) and incubated with a 
secondary antibody linked to horseradish peroxidase for 1 hour at room temperature. After 
three washes in TBS-T, the proteins were visualized using enhanced Clarity™ Western 
ECL Blotting Substrate (Biorad) and the ChemiDoc™ MP System (Biorad). 
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4 Results	  
 
4.1 Myc	  is	  a	  downstream	  target	  of	  p53	  	  
 
Our group has contributed to elucidate one of the CSC specific mechanisms for breast 
cancer progression: the role of p53 in governing the SCs mode of division, favoring 
asymmetric segregation. Loss of function of p53 was shown to lead to unlimited expansion 
of a population enriched in CSCs, as assessed by mammosphere assay and limiting dilution 
transplantation (Cicalese, Bonizzi et al. 2009). Nevertheless p53 is implicated in a plethora 
of pathways involving responses to stress and cell cycle arrest. Therefore, the role of p53 
in the regulation of SC divisions requires further analyses to understand the mechanisms 
with which this function is carried out. Following a candidate gene approach and based on 
the available knowledge that places Myc as a target of p53 (Ho, Ma et al. 2005, Sachdeva, 
Zhu et al. 2009, Li, He et al. 2012), we decided to evaluate the role of the myc oncogene as 
the key downstream effector of p53 loss in breast cancer. 
 
4.1.1 Myc	  is	  over-­‐expressed	  in	  ErbB2	  mammary	  tumors	  
 
As a first step we investigated whether Myc is overexpressed in our murine model of 
spontaneous breast tumorigenesis, driven by the ErbB2 oncogene. This model consists of a 
transgenic mouse carrying a constitutively active form of the ErbB2 oncogene (with the 
activating mutation Val664 to Glu664) under the control of the Mouse Mammary Tumor 
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Virus (MMTV) promoter (Muller, Sinn et al. 1988). It is characterized by attenuated p53 
signaling and enhanced self-renewal potential, as assessed by mammospheres re-plating 
ability compared to non-tumor mammary cells (Cicalese, Bonizzi et al. 2009). 
Furthermore, it was demonstrated that tumors that are formed in the MMTV-ErbB2 mouse 
follow a CSC model, as it was possible to isolate a tumorigenic population, marked by the 
expression of Sca1, from a non-tumorigenic one (Grange, Lanzardo et al. 2008). 
To evaluate levels of Myc protein, we collected three mammary tumors from independent 
MMTV-ErbB2 transgenic mice and mammary glands of WT FVB mice, as control. We 
purified the epithelial cells by column-based negative selection of cells carrying antigens 
specific for hematopoietic or endothelial tissues (Ter119, CD45, CD31) and prepared cell 
lysates for protein quantification. The western blot in Figure 4-1 shows that Myc is 
overexepressed in ErbB2-tumors, as compared with the normal tissue, though protein 
levels vary significantly among different tumors.  
 
Figure 4-1: Myc expression in MMTV-ErbB2 tumors ex vivo. 
Cells from three independent tumors arisen in 3 months old MMTV-ErbB2 mice and from adult WT mice 
were collected and CD31negTer119negCD45neg cells purified through column-based negative selection. 
Levels of Myc were analyszed by Western Blot using anti-Vinculin antibody as loading control. 
 
To investigate whether over-expression also occurred in a population enriched in CSCs, we 
took advantage of the “mammospheres assay”. Mammary cells endowed with self-renewal 
potential can be propagated in culture in anchorage-independent conditions, in the absence 
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of serum and in the presence of selected growth factors. Under those conditions, they 
expand clonally to form spheroids, which contain SCs and early progenitors (Dontu, 
Abdallah et al. 2003, Liao, Zhang et al. 2007), thus they represent a useful tool to study SC 
properties and functions.  
Therefore, we analyzed levels of Myc (mRNA and protein) in mammospheres derived 
from either WT or MMTV-ErbB2 transgenic mice. The data in Figure 4-2 indicate that 
Myc transcript expression is strongly up regulated in a CSC-enriched population of our 
tumor model. Equally, Myc protein levels were also increased in mammospheres obtained 
from two independent tumors, as compared to WT mammospheres (Figure 4-3).  
 
Figure 4-2: Myc mRNA is over-expressed in tumor mammospheres 
Myc expression was assessed in WT (n=7) and MMTV-ErbB2 tumor (n=5) derived mammospheres by qPCR 
analysis of Myc mRNA (means ± standard deviation). Values are expressed as fold change relative to WT 
samples. Myc expression was normalized against the GusB housekeeping gene. Significance of differences 
between the two samples was calculated by t-test (*pvalue<0.05). 
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Figure 4-3: Myc protein is over-expressed in tumor mammospheres 
Western blot analysis of the expression of Myc in WT mammospheres and in 2 independent MMTV-ErbB2 
tumor cultures. Vinculin used as loading control. 
	  
4.1.2 Myc	  over-­‐expression	  is	  the	  consequence	  of	  p53	  loss	  of	  function	  
 
P53 is not mutated in our tumor model, nevertheless its signaling is attenuated, as shown 
by its blunted response upon DNA damage (Cicalese, Bonizzi et al. 2009). To investigate 
whether the up-regulation of Myc in ErbB2-tumor cells is a consequence of reduced p53 
activity, we decided to analyze the effect of p53 reactivation on Myc levels, by in vitro 
administration of Nutlin-3. Nutlin-3 is a small molecule antagonist of Mdm2-p53 binding, 
that, preventing its degradation, stabilizes p53 and restores its levels in the cells (Vassilev 
2004).  
We first investigated the effective restoration of p53 function in Nutlin-treated tumor 
mammospheres, by measuring p53 response after Adriamycin administration, a known 
DNA damage agent inducing p53-dependent apoptosis (Wang, Konorev et al. 2004). The 
result confirms that when p53 is stabilized by Nutlin administration (2.5 or 10 µM) it re-
gains its functional competences, as established by the increase in the levels of its 
phosphorylated and active form (phospho-S15) and up-regulation of its target p21 during 
the 4 to 8 hours exposure to doxorubicin (Figure 4-4). 
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Figure 4-4: Nutlin-3 restores functional p53 signaling 
ErbB2 tumor cells were plated and treated with Nutlin 2.5 or 10 µM for 16 hours and then administered with 
Adriamycin (0.5µM) for 4 or 8 hours, as indicated. Western blot analysis of the expression of phosphorylated 
form of p53 (phospho Serine 15) and p21. Vinculin used as loading control. 
 
 
 
We then analyzed the levels of Myc in the ErbB2 tumor mammospheres, untreated or 
treated with Nutlin-3 for 72h. The results are reported in Figure 4-5 and show that Myc 
mRNA is severely down-regulated, and its expression is brought back to the levels of WT 
mammospheres. Accordingly, Myc protein expression decreases upon Nutlin treatment of 
~20%-30% of its levels, depending on the tumor under analysis (Figure 4-6). 
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Figure 4-5: Effects of p53 restoration on Myc mRNA levels 
Myc expression was assessed in WT (n=7), MMTV-ErbB2 tumor (n=3) and 3 corresponding ErbB2 tumors 
treated with Nutlin-3 (2.5µM) for 72h by qPCR analysis of Myc mRNA (means ± standard deviation). 
Values are expressed as fold change relative to WT samples. Myc expression was normalized against the 
GusB housekeeping gene. Significance of differences between treated and not-treated samples was calculated 
by paired t-test (*pvalue<0.05). 
 
 
 
Figure 4-6: Effects of p53 restoration on Myc protein levels 
Western blot analysis of the expression of Myc in two ErbB2 tumors grown as mammospheres. Cells were 
untreated or treated with Nutlin-3 (2.5µM) for 72h. Vinculin used as loading control. 
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To exclude p53-independent effects of Nutlin, we administered Nutlin to p53-/- derived 
mammospheres. No down regulation of Myc could be observed at any of the indicated 
timepoints after compound administration (Figure 4-7). 
 
Figure 4-7: Nutlin administration has no effect on myc regulation in the absence of p53 
P53-/- cells were plated as mammospheres in the presence or absence of Nutlin-3 (2.5µM). Cells were 
collected 24, 48 and 72 hours after plating and levels of Myc were evaluated by western blot analysis. 
Vinculin used as loading control. 
 
4.1.3 Myc	  is	  a	  target	  of	  p53	  also	  in	  non	  tumor	  contexts	  
 
To investigate whether p53 and Myc are epistatically linked independently of the tumor 
context, we analyzed levels of Myc expression in normal mammary cells, as a function of 
p53 expression and activation (p53+/- and -/- cells, Adriamycin treated WT cells, p53ER 
expression in p53-/- cells).  
 
a) First, we evaluated Myc mRNA and protein levels in mammospheres derived from 
the mammary gland of p53+/- or p53-/- mice against levels in mammospheres from 
WT glands. Interestingly, while we observed a marked over-expression of Myc 
protein levels in the p53-/- mammospheres, levels in the p53+/- mammospheres 
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were approximately midway between those in p53 null and in WT spheres, 
suggesting that Myc abundance is strongly dependent on the levels of p53 (Figure 
4-8, right). Again, Myc mRNA expression mirrored the protein levels (Figure 4-8, 
left). 
 
Figure 4-8: Myc levels depend on p53 abundance in normal mammary stem and progenitor cells 
LEFT: Myc expression was assessed in WT (n=7), p53+/- (n=3) and p53-/- (n=4) mammospheres by qPCR 
analysis of Myc mRNA (means ± standard deviation). Values are expressed as fold change relative to WT 
samples. Myc expression was normalized against the GusB housekeeping gene. Significance of differences 
between samples and WT was calculated by t-test (*pvalue<0.05). RIGHT: representative western blot 
analysis of Myc protein in WT, p53+/- and p53-/- mammospheres. Vinculin used as loading control. 
 
b) To exclude an indirect effect of p53 on Myc levels, possibly mediated by the high 
proliferating rate of p53-/- cells, we “acutely” activated p53 by DNA damage and 
evaluated the effect on Myc expression. WT, p53+/- and p53-/- mammospheres 
were treated with Adriamycin (0.5 µM) and cells were collected after 2, 4, 6 and 8 
hours. The histogram in Figure 4-9 depicts the levels of Myc expression as 
measured by qPCR. Myc mRNA appears progressively down-regulated in the 
presence of a functional p53 (both in WT and in p53+/- mammospheres), while in 
the p53-/- mammospheres it is not perturbed at any of the timepoints. The western 
blot in Figure 4-10, however, shows that, levels of the Myc protein in WT 
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mammospheres are only slightly down-regulated, despite strong p53 activation and 
up-regulation of p53-transcriptional targets (Figure 4-10, right). 
 
Figure 4-9: Effects of p53 acute stimulation on Myc mRNA levels 
Myc expression was assessed by qPCR analysis of Myc mRNA in WT, p53+/- and p53-/- mammospheres 
treated with Adriamycin (0.5µM) for the indicated time points (means ± standard deviation of three 
independent experiments). Values are expressed as fold change relative to untreated (UT) samples of each 
cell-type. Myc expression was normalized against the GusB housekeeping gene. Significance of differences 
between treated and not-treated samples was calculated by t-test (*pvalue<0.05). 
 
Figure 4-10: Effects of acute stimulation of p53 on Myc protein expression 
LEFT: Western blot analysis of the expression of Myc and the phosphorylated form of p53 (phospho Serine 
15) in WT mammospheres upon Adriamycin treatment (0.5µM) for the indicated times. Vinculin used as 
loading control. RIGHT: qPCR analysis of selected targets of p53 activation (p21 and Noxa genes). Values 
are expressed as average fold change relative to untreated (UT) sample, error bars indicate standard deviation 
of three biological replica.  
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Likely, the degree of down-regulation of Myc is not fully appreciable given the basal low 
levels of the Myc protein in WT cells. However, when we performed the same experiment 
in p53+/- mammospheres, which harbor one functional allele of p53 and higher basal 
levels of Myc, we observed a more evident down-regulation of Myc upon DNA damage, as 
opposed to the absent regulation of Myc levels in the p53-/- cells (Figure 4-11). As further 
evidence, we performed the same Adriamycin treatment on NMuMG cells, a murine breast 
immortalized line, and again we noticed a striking down-regulation of Myc expression in 
response to p53 acute activation (Figure 4-12). 
 
 
Figure 4-11: Effects of acute stimulation of p53 by DNA damage in p53+/- and p53-/- mammospheres 
Western blot analysis of the expression of Myc and the phosphorylated form of p53 (phospho Serine 15) in 
p53+/- and p53-/- mammospheres upon Adriamycin treatment (0.5µM) for the indicated times. Vinculin used 
as loading control. P53+/+ ESCs are loaded as positive control for the p53 band.  
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Figure 4-12: Effects of acute stimulation of p53 by DNA damage in NMUMG cells. 
Western blot analysis of the expression of Myc and phosphorylated form of p53 (phospho Serine 15) in 
NMUMG cell line upon Adriamycin treatment (0.5µM) for the indicated times. Vinculin used as loading 
control.  
 
c) Finally, taking advantage of a retroviral expression vector (pBABE-puro) harboring 
an inducible p53-ER sequence, we re-expressed p53 in p53-/- mammospheres by 4-
OHT administration (200nM). The effectiveness of restoration is demonstrated by 
the up-regulation of p53 transcriptional targets p21 and Bax as shown in the qPCR 
in Figure 4-13, left. Through this last approach, we could also observe acute down-
regulation of both Myc protein and RNA levels at all of the time-points following 
4-OHT treatment (Figure 4-13, left and right). 
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Figure 4-13: Effects of re-expression of p53 in p53-/- mammospheres  
LEFT: qPCR analysis of Myc mRNA in p53-/- cells transduced with pBABE-puro-p53ER vector and treated 
with 4-OHT (200µM) for the indicated times. Values are expressed as average fold change relative to 
untreated (UT) sample, bars indicate standard deviation of three biological replica. RIGHT: Western blot 
analysis of the expression of Myc in WT mammospheres upon 4-OHT treatment at the indicated time points. 
Vinculin used as loading control.  
 
 
 
 
All together these data suggest that a functional p53, either directly or indirectly, imposes a 
control over the levels of Myc mRNA and protein. When p53 is absent, as in the knock-out 
murine model, or dysfunctional, as in our ErbB2 tumour model, this control is lost and 
Myc levels are de-regulated, and this, in turn, could be the causative mechanism that leads 
to the unlimited growth described in the mammosphere assay (Cicalese, Bonizzi et al. 
2009). 
 
Notably, WT mammospheres down-regulate Myc during their growth (in a 5-days culture, 
from single cells to formed mammospheres), and exit the cell cycle (Figure 4-14). In the 
erbB2 tumor spheres, instead, Myc expression remains stable during the culture; cells do 
not exit the cell cycle and continue to proliferate (Figure 4-14). Therefore, the extended 
replicative potential of tumor spheres might be the consequence of both Myc over- 
expression and de-regulation. 
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Figure 4-14: Myc is de-regulated in ErbB2 tumors  
TOP: schematic representation of mammosphere growth over the days of culture. Mammospheres are used a 
surrogate of an organ development (the mammary gland) and originate from a single cell that gives rise to 
more differentiated progenitors. MIDDLE: Western blot analysis of the expression of Myc in WT and ErbB2 
mammospheres during their formation. Vinculin used as loading control. BOTTOM: Cell cycle analysis of 
mammospheres at the indicated time points (BrDU coupled with PI staining). Cycling cells are defined as 
cells positive for BrDU (S-phase) and with 2n DNA content (G2/M). Values are calculated as percentage of 
cycling cells on day1 (mean ± standard deviation of three independent experiments). 
	  
4.1.4 The	  Myc	  transcriptional	  program	  is	  activated	  in	  ErbB2-­‐tumor	  cells	  and	  depends	  
on	  levels	  of	  p53	  
 
We then investigated whether Myc overexpression in ErbB2 mammary cells correlates 
with its transcriptional activity. Since the transcriptional program of Myc is cell-context 
and cell-state dependent (Littlewood, Kreuzaler et al. 2012, Tansey 2014), we first defined 
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the transcriptional effects of Myc in mammary epithelial cells. To this end, we performed 
RNAseq analyses of WT mammospheres transduced with a lentiviral vector expressing the 
inducible MycER fusion protein (fusion of human Myc with a modified version of the 
estrogen receptor), grown in the absence of the 4-OHT ligand (Littlewood, Hancock et al. 
1995). Under these conditions, MycER is expressed at moderate levels in the nucleus of 
mammary cells and induces their immortalization [(Pasi, Dereli-Oz et al. 2011) and see 
next section].   
Comparison of the normalized-reads-count per gene between MycER cells and control 
cells (transduced with the corresponding empty vector) led to the identification of 5,618 
differentially regulated genes (cut-off on the q-value: lower or equal to 0.01) out of the 
around 13,000 genes expressed in our system. Of them, 3,023 genes are up-regulated 
compared to the empty vector-expressing cells and 2,595 genes result down-regulated.  
To investigate whether the Myc transcriptional-program is activated in the ErbB2 
mammary cancer-cells, we performed Gene Set Enrichment Analysis (GSEA) 
(Subramanian, Tamayo et al. 2005) of the MycER dataset in ErbB2 cells. 
We first generated RNAseq datasets of three independent ErbB2 tumors in mammosphere 
cultures, and calculated the ratio of the mean of their normalized reads to that of WT 
mammospheres (n=3). A total of 2,460 genes resulted differentially expressed in tumors 
compared to WT cells. We then created two separate lists for the up-regulated (ErbB2-UP 
1,162 genes) and the down-regulated (ErbB2-DOWN 1,298 genes) and aligned those to the 
ranked list of Myc transcriptional targets.  
In the Gene Set Enrichment analyses, each gene set is ordered according to the regulation 
of a query dataset from the most up-regulated to the most down-regulated genes. If the 
gene set under analysis is not correlated with the query dataset, genes will be distributed 
randomly in the query dataset. Conversely, if the two datasets are correlated (positively or 
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negatively), the distribution will be asymmetric. GSEA computes the overlap between the 
gene sets mathematically, returning a normalized enrichment score (NES), which expresses 
the overlap within the two signatures, and a FDR (or q-value) as measure of statistical 
significance. We performed the GSEA analysis distinguishing each cell-type specific 
signature in UP and DOWN regulated genes that were then ranked according to their 
regulation in the MycER dataset.  
GSEA analysis of ErbB2 and MycER datasets showed impressive correlation between the 
up-regulated genes in ErbB2 tumors and the core of genes that are up-regulated in WT 
cells by the presence of MycER; a similar correlation is also observed between ErbB2 
tumor down-regulated genes and the genes that localize towards the bottom side (more 
down-regulated) of the ranked MycER list of target genes (Normalized Enrichment Score, 
NES = 4.9 and -4.6, respectively) (Figure 4-15).  
 
Figure 4-15: MycER signature in MMTV-ErbB2 tumors 
Gene set enrichment analysis was performed to correlate the tumor (ErbB2-driven) transcriptional program 
with gene expression changes upon MycER infection (5,618 genes). The normalized enrichment score (NES) 
is shown and significance (FDR, qvalue) was reported to be approximately equal to 0.  
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We then asked whether the Myc transcriptional-program is dependent on p53 function. To 
do so, we analyzed the enrichment of the MycER program in p53-/- mammospheres. We 
performed RNAseq analyses of WT (n=3) and p53-/- (n=3) mammospheres and generated 
lists of p53ko-UP and p53ko-DOWN using the same cut-off criteria described for the 
previous RNAseq datasets (5,192 differentially regulated genes: 2,462 UP; 2730 DOWN). 
Once run on the GSEA software, we observed high enrichment of the MycER signature in 
the p53null genetic context, similarly to that of our tumor model (Figure 4-16), suggesting 
that a vast part of Myc activity is enhanced in the absence or impairment of p53. These 
findings further confirm that Myc de-regulation in tumors can be widely attributed to the 
missing functionality of p53 signaling. 
 
Figure 4-16: MycER signature in p53-/- cells 
Gene set enrichment analysis was performed to correlate the p53-/- transcriptional program with gene 
expression changes upon MycER infection (5,618 genes). The normalized enrichment score (NES) is shown 
and significance (FDR qvalue) was reported to be approximately equal to 0 
 
 
Finally, to address this point directly, we investigated whether the Myc-transcriptional 
program in the ErB2 cells depends on p53. To this end, we performed RNAseq analyses of 
ErbB2 cells treated, or not, with Nutlin-3 (n = 3 independent tumors). In this case, the UP 
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and DOWN lists of genes were obtained by calculating the paired ratio of gene expression 
and then the GSEA analysis was performed with the same cut-off criteria described earlier. 
Strikingly, when we ran the Nutlin-UP and DOWN lists on the GSEA software, we 
observed an enrichment curve profile completely opposite to that of the ErbB2 tumor. 
Indeed, the up-regulated side of the ranked list appears enriched for the “DOWN-list” and 
vice versa for the down-regulated side, thus demonstrating that the restoration of p53 
induces a transcriptional response that completely reverts the MycER-dependent activity in 
ErbB2 tumors (Figure 4-17).  
 
Figure 4-17: MycER signature in MMTV-ErbB2 tumors treated with Nutlin-3. 
Gene set enrichment analysis was performed to correlate the transcriptional program of ErbB2 tumors treated 
with Nutlin-3 (2.5µM) with gene expression changes upon MycER infection (5,618 genes). The normalized 
enrichment score (NES) is shown and significance (FDR, qvalue) was reported to be approximately equal to 
0.  
 
Collectively these data demonstrate that Myc transcriptional activity is enhanced in the 
ErbB2 cancer cells, thus mirroring the data of its overexpression, and that, in mammary 
cells, it is strongly dependent on the levels of a functional p53. 
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All together, we have shown that p53 and Myc are epistatically related and that the loss of 
p53 has remarkable effects on the de-regulation of Myc levels in cell populations enriched 
for mammary SCs and breast CSC. 
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4.2 De-­‐regulated	   Myc	   extends	   the	   life	   span	   and	   proliferative	   potential	   of	  
mammary	  stem	  and	  progenitor	  cells	  
4.2.1 Transgenic	  R26-­‐MycER	  mice	  as	  a	  tool	  to	  induce	  de-­‐regulation	  of	  Myc	  levels	  
 
It emerges from our data that the de-regulation of Myc levels due to loss of p53 has 
important implications for mammosphere growth in culture. To define the effects of this 
de-regulation on mammary epithelial cells, we took advantage of a murine model 
harboring an inducible Myc-ERT2 allele within the Rosa26 locus, whose translocation into 
the nucleus can be finely tuned by the administration of 4-OHT (Murphy, Junttila et al. 
2008).  
Mammary glands derived from these animals were collected and digested enzymatically in 
order to obtain single cell suspensions. Cells were then plated for mammosphere culture 
and dosage-dependent effects of 4-OHT evaluated in terms of proliferation potential and 
sphere forming ability. Specifically, the cells were plated at a clonal density of 20,000 
cells/ml in 6 well plates and serially passaged in the presence or absence of 4-OHT. At 
each passage, we enumerated the spheres, disaggregated them, and counted the total 
number of cells, in order to measure their replicative potential (i.e., cells/sphere). The data 
were then arranged into cumulative growth curves showing the variation in the number of 
mammospheres and cells during passages. As shown in Figure 4-18 bulk mammospheres 
not treated with 4-OHT progressively decrease in number, exhaust in culture after 6-7 
passages and cannot be further propagated, confirming that WT SCs have limited lifespan 
and self-renewing potential, as previously shown by our group (Cicalese, Bonizzi et al. 
2009). Immunofluorescence analysis demonstrated that basal levels of nuclear Myc in 
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heterozygous Rosa26-MycER derived mammospheres were comparable to those of WT 
mammospheres, while when 4-OHT was administered, a bright nuclear signal could be 
detected, thus indicating that the fine-tuning of the inducible system is tightly controlled 
Figure 4-19. As previously observed in other cellular systems, different levels of Myc 
expression (e.g. different doses of 4-OHT) elicit different biological effects (Murphy, 
Junttila et al. 2008). When 500 nM or 1 µM 4-OHT was administered, mammospheres 
derived from heterozygous Rosa26-MycER mice rapidly faced self-exhaustion (Figure 
4-18) due to Myc-dependent apoptotic cellular death (Figure 4-20). The same treatment 
did not induce cell death of spheres derived from mice of the same colony but negative for 
the presence of the transgene (from here on called Rosa26-MycER WT) (Figure 4-20). 
Intriguingly, when the sphere cultures were exposed to lower doses of 4-OHT (20 nM or 
200 nM), they exhibited a remarkable increase in their self-renewing potential. Indeed, the 
cumulative sphere number approximated an exponential curve (R2= 0.95 and 0.99 
respectively) with a growth rate going from 121% for the 20 nM dose to 161% for the 200 
nM (Figure 4-18), and the spheres could be passaged indefinitely (data not shown). 
Strikingly, this behavior of Myc-ER mammospheres was undistinguishable from that of 
p53 KO or ErbB2-tumor mammospheres (Cicalese, Bonizzi et al. 2009).  
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Figure 4-18: Growth curve of Rosa26-MycER mammospheres. 
Semi-logarithmic plot of Cumulative Sphere numbers. Numbers were obtained from serial replating of 
Rosa26-MycER mammospheres in the absence or continuous presence of different concentrations of 4-OHT. 
Each dot in the curve represents the mean of six independent curves; error bars indicate the standard 
deviation. Regression analysis was performed to obtain trend lines (dashed lines) that best approximate the 
curves. Growth rates (GR) and coefficients of determination (R2) for each trend line are reported inside the 
graph. 
 
Figure 4-19: Myc translocation is inducible upon 4-OHT administration. 
Immunofluorescence analysis of Myc expression with a Myc-specific antibody in WT and Rosa26-MycER 
heterozygous (HE) untreated or treated with 4-OHT (200 µM). Nuclei were counter-stained with Dapi (right 
panels).  
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Figure 4-20: Morphology of mammospheres treated with different doses of 4-OHT. 
Representative images of spheres derived from Rosa26-MycER mice heterozygous (top) or WT (bottom) for 
the transgenic allele. Both cultures were exposed to the lowest and highest dose of 4-OHT tested (20nM and 
1µM) and pictures were taken at the third passage of the serial replating assay. Scale bar as represented. 
 
Furthermore, compared to the untreated control, a dramatic increase in the total number of 
cells and in mammosphere size (number of cells per sphere) was observed upon low doses 
of 4-OHT, suggesting that treated Rosa26-MycER mammospheres also possess increased 
replicative potential (Figure 4-20 and Figure 4-21). As shown in other systems (Reavie, 
Della Gatta et al. 2010), these observations indicate that tight regulation of Myc protein 
expression is critical in the control of numbers of mammary stem and progenitor cells. 
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Figure 4-21: Growth curve of Rosa26-MycER cells grown as mammospheres. 
Semi-logarithmic plot of Cumulative Cell number. Numbers were obtained from serial replating of Rosa26-
MycER mammospheres in the absence or continuous presence of the two lowest doses of 4-OHT. Each dot in 
the curve represents the mean of six independent curves; error bars indicate the standard deviation. 
Regression analysis was performed to obtain trend lines (dashed lines) that best approximate the curves. 
Growth rates (GR) and coefficients of determination (R2) for each trend line are reported inside the graph. 
 
 
 
4.2.2 Low	   levels	   of	   Myc	   expand	   the	   mammary	   stem	   cell	   pool	   and	   are	   able	   to	  
reconstitute	   the	   mammary	   gland	   in	   transplantation	   assays,	   without	   inducing	  
transformation	  
 
The above results show that the continuous presence of low levels of myc is able to confer 
increased self-renewal and replicative potential to mammary stem cells and progenitors. 
We then decided to investigate the consequences of these effects on the development of the 
mammary gland in vivo. To this end, we planned transplantation experiments of our 
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Rosa26-MycER mammospheres in the cleared fat pad of recipient mice fed with a 4-OHT-
containing diet.  
Tamoxifen is an ER antagonist that is used in the treatment of ER positive breast cancer 
(Mouridsen, Palshof et al. 1978). Given that estrogen and its receptor have essential roles 
in mammary gland development, we first investigated the effects of continuous tamoxifen 
treatment on ductal development and function. Indeed, it was reported that acute doses of 
tamoxifen change the distribution of mammary epithelial populations (Shehata, van 
Amerongen et al. 2014), and severely affect mammary gland development when 
administered at puberty (3 administrations at 1.5mg; 1 administration at 2.5mg; (Rios, Fu 
et al. 2014)). We fed adult control mice (same genetic background of the Rosa26-MycER 
mice) with 4-OHT-containing food continuously for 2 weeks (40mg/kg, around 1mg per 
mouse every 3-4 days), and evaluated the distribution of mammary cell types using known 
surface markers (EpCAM; CD49f; CD61) (Guo, Keckesova et al. 2012). As shown in 
Figure 4-22, the effect of a Tamoxifen diet on the distribution of mammary progenitor 
populations is remarkable and leads to a significant decrease in the most differentiated 
population of luminal cells, and to a strong and unexpected increase in the percentage of 
basal (SC-enriched) cells, thus suggesting an impairment in the terminal differentiation of 
the treated glands. Also, when mice were treated at puberty (21 days after birth), we 
observed a dramatic decrease in the lin- EpCAM positive cells, hinting to potential 
disruption of mammary gland development, as previously shown (Rios, Fu et al. 2014). 
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Figure 4-22: In vivo administration of 4-OHT in control adult or pubertal mice.  
8 weeks or 3 weeks old mice were fed for two weeks with 4-OHT containing-food or with standard diet; 
mammary glands were then collected, single cells were stained for surface markers and their intensity was 
assessed by FACS. LEFT: percentage of Luminal Mature (EpCAM+/CD49f-/CD61-), Luminal Progenitor 
(EpCAM+/Cd49f-/CD61+) and Mammary stem cells (MaSC - EpCAM+/Cd49f+/CD61+) within the Lin-
(CD31-/Ter119-/CD45-)/EpCAM+ cell population derived from the mammary glands of 8 week old mice. 
Values are shown as the mean of the relative percentage of each population from three independent mice 
treated with 4-OHT food and from two mice on standard diet; error bars indicate the standard deviation; 
significance of differences between the two experimental groups was calculated by t-test (*pvalue <0.05). 
RIGHT: percentage of Lin-/EpCAM+ cells in total mammary cell populations from 3-week-old mice. Values 
are shown as the mean of the relative percentage of each population from three independent mice treated with 
4-OHT food and from two mice on standard diet; error bars represent the standard deviation; significance of 
differences between the two experimental groups was calculated by t-test (*pvalue <0.05).  
 
As an alternative to the continuous administration of 4-OHT, we decided to use the 
lentiviral vector mentioned in section 4.1.4 (Littlewood, Hancock et al. 1995). Our group 
demonstrated that WT mammospheres transduced with the aforementioned vector undergo 
a severe p53-dependent apoptotic response upon induction with 4-OHT (Pasi, Dereli-Oz et 
al. 2011). Conversely, if cultured in the absence of 4-OHT, MycER infected cells become 
immortalized, expand unlimitedly in culture, and form larger mammospheres, suggesting 
that they possess increased self-renewal and replicative potential (Pasi, Dereli-Oz et al. 
2011). This behavior is identical to that observed for the Rosa26-MycER spheres at low 
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doses of 4-OHT, suggesting that it could be due to a leakage in the Myc-ER infected cells 
of the ER conditional system. Immunofluorescence analysis of Myc nuclear translocation 
revealed, indeed, that while basal levels of Myc are almost undetectable, upon infection 
with the MycER vector a slightly higher nuclear signal could be detected also in the non-4-
OHT treated mammospheres (Figure 4-23). Real time PCR (qPCR) of three Myc targets 
(Nucleolin; ODC1 and CAD) revealed upregulation of their expression upon MycER 
mammosphere infection, in the absence of 4-OHT induction, as compared to the control 
mammospheres transduced with the empty-vector (Figure 4-24). Likewise, qPCR showed 
that endogenous Myc expression is down regulated as expected by the auto regulatory loop 
that Myc exerts on its own promoter (Figure 4-24).  
 
 
Figure 4-23: Immunofluorescence staining for Myc expression in control or 4-OHT untreated or 
treated MycER infected cells. 
Staining of single cell suspensions from secondary WT mammospheres transduced with an empty vector 
(top) or MycER, in the absence (middle) or presence of 4-OHT (200 µM, bottom) for 72 hours, with a Myc 
specific antibody. Nuclei were counter-stained with Dapi (right panels).  
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Figure 4-24: Myc targets are up-regulated in cells transduced with MycER in the absence of any 4-
OHT stimulus.  
RT qPCR of selected targets of Myc was performed in WT mammospheres transduced with Empty or 
MycER vectors and cultured for the indicated time points (means ± standard deviation of two biological 
replicas). Values are expressed as fold change relative to the empty vector expression (Empty vector = 1). 
Each gene expression was normalized against the GusB housekeeping gene.  
 
 
Interestingly, the extent of regulation of the Myc targets was comparable to that observed 
in the Rosa26MER mammospheres upon 72h of low doses 4-OHT treatment (Figure 
4-25). Therefore, we concluded that, prior to any 4-OHT induction, the lentiviral construct 
recapitulates what we saw in the inducible R26-MycER murine model, demonstrating that 
it represents a suitable system as a substitute for the Tamoxifen in vivo treatment 
experiments.  
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Figure 4-25: Myc transcriptional activity upon MycER infection is enhanced to the same extent to 
what observed for Rosa26-MycER mammospheres upon low doses of 4-OHT stimulation. 
RT qPCR of selected targets of Myc was performed in WT mammospheres transduced with Empty or 
MycER vectors and cultured for 72 hours (means ± standard deviation of two biological replica) and in 
Rosa26-MycER mammospheres upon 72 hours induction by 4-OHT at the indicated doses (means ± standard 
deviation of five biological replica). Values are expressed as fold change relative to Empty vector expression 
or untreated cells (both = 1). Each gene expression was normalized against the GusB housekeeping gene.  
 
 
Thus, we moved to an in vivo setting using Myc-ER infected mammospheres. To 
investigate whether continuous presence of low levels of Myc leads, in vivo, to an increase 
in mammary stem cell content, we performed limiting dilution transplantation experiments 
of the mammospheres transduced either with the MycER vector or with the corresponding 
empty vector in the cleared fat pad of three-weeks old virgin recipients. As shown in Table 
4-1, MycER infected cells are able to give rise to positive outgrowths when as little as 100 
cells were transplanted, unlike the empty vector transduced cells. These data suggest that 
low levels of Myc expression lead to an expansion of the pool of stem cells in vivo.  
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Table 4-1: Limiting dilution transplantation experiment on mammospheres transduced with Empty 
vector or MycER. 
Cells suspension from WT mammospheres infected with Empty or MycER vectors were inoculated in 
recipient mice in limiting dilution conditions (500 and 100 cells). Results show the number of positive 
outgrowths as defined by the presence of epithelial structures with radial organization in stained whole 
mounts 12 weeks after the injection. SC frequencies (estimates and upper/lower limits) were calculated by 
limiting dilution analysis, as described in the Materials and Methods section. The significance of the 
difference in SC frequency is indicated by the p-value (<0.05). 
 
 
We then investigated whether low-levels of Myc expression initiates tumorigenesis in vivo. 
To address this question, we transplanted a total of 15 mice and kept them under 
observation for tumor formation for up to 1 year. Notably, no palpable masses could be 
detected in our cohort of mice and analysis of the outgrowths after whole mount staining 
showed that the morphology of the epithelial tree was not altered (Figure 4-26). Taken 
together these data demonstrate that low levels of Myc expression induce expansion of SC 
numbers in vivo, without initiating the transformation process.   
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Figure 4-26: Whole mount staining of a positive outgrowth resulting from the injection of MycER 
expressing cells. 
Representative image of carmine alum whole mount staining of a reconstituted gland after injection of 100 
MycER transduced cells. Scale bar as indicated.  
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4.3 De-­‐regulation	  of	  Myc	  expression	   increases	  numbers	  of	  mammary	  SCs	  by	  a	  
dual	  mechanism	  
 
The results described in the previous chapters showed Myc to be a downstream target of 
p53 in mammary stem and progenitor cells: at the molecular level we observed a negative 
interplay that is dependent on p53 function, with Myc being constitutively expressed in the 
absence of p53. Accordingly, we saw that constitutive Myc expression phenocopies the 
biological effects of p53-loss, e.g. expansion in number of SCs, both in vitro and in vivo. 
We then investigated the biological mechanisms underlying the effects of Myc on SC 
numbers, starting from those documented for p53-loss.  
It has been shown that p53 acts as a master regulator of homeostasis within several tissues, 
by controlling the size of the SC pool (Bieging, Mello et al. 2014). The effects of p53 on 
SCs are to ensure the correct balances between quiescence versus proliferation (Liu, Elf et 
al. 2009) and asymmetric versus symmetric self-renewing divisions (Cicalese, Bonizzi et 
al. 2009). Both functions are considered part of its well-known role as a tumor suppressor 
in cells, as the increase in the rate of SC symmetric division is thought to be one of the 
causes of the formation of a malignant clone (Morrison and Kimble 2006). P53 was also 
shown to affect numbers of SCs indirectly, by inhibiting reprogramming of more 
differentiated population into SCs. This was shown both in the context of iPS generation 
(Hong, Takahashi et al. 2009) and in physiological conditions (Tschaharganeh, Xue et al. 
2014); our group’s unpublished data). This is also very relevant for the tumor suppressive 
function of p53, as de-differentiation and developmental plasticity, particularly in epithelial 
tissues, were demonstrated to be key mechanisms supporting cancer growth (Mani, Guo et 
al. 2008). 
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Notably, we have previously reported that constitutive expression of low levels of Myc 
(those ensured through the “leaky” MycER vector) is able to skew the modality of division 
of mammary SCs towards symmetry, as demonstrated by the segregation of the cell-fate 
determinant Numb and time-lapse analysis of SC first mitotic events (Pasi et al. 
unpublished results). Furthermore, low levels of Myc also conferred mammosphere 
replating ability to progenitors in culture, suggesting that Myc confers self-renewal 
properties to progenitors (Pasi, Dereli-Oz et al. 2011). Thus, we investigated whether Myc 
induces reprogramming of mammary progenitors into SCs, using the Rosa26-MycER 
murine model (for in vitro assays) and the aforementioned MycER lentiviral construct (for 
in vivo assays). 
 
4.3.1 Effect	  of	  Myc	  on	  the	  ability	  of	  mammary	  progenitors	  to	  form	  spheres	  
 
To separate the effects of enforced expression of Myc on SCs or progenitors, we purified 
these two populations, taking advantage of the PKH26 assay developed in our laboratory 
(Cicalese, Bonizzi et al. 2009, Pece, Tosoni et al. 2010). PKH26 is a lipophilic dye that 
binds the cell membrane and segregates in daughter cells after each cell division, such that 
the intensity of staining inversely correlates with the number of undergone cell divisions 
(Lanzkron, Collector et al. 1999). This method exploits one of the well-accepted properties 
of adult SCs, that is, their being mostly dormant (quiescence). By this assay, cell 
suspensions obtained from mammosphere cultures are separated in at least two subsets, 
among which only those retaining the dye (top 1.5% most brilliant; PKHhigh) contain SCs, 
while those where the intensity of the dye appears most diluted (bottom 25%; PKHneg) 
comprise lineage-restricted cells, as demonstrated by limiting dilution transplantation 
(Cicalese, Bonizzi et al. 2009). 
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PKH negative cells consist of a heterogeneous population of cells that has gone through 
multiple rounds of division. These actively cycling cells were previously characterized as 
mono-potent progenitors, able to give rise to either epithelial or, rarely, myoepithelial 
colonies, in 2D-differentiation matrigel assays and unable to form mammospheres upon 
serial replating (Pece, Tosoni et al. 2010) or a mammary gland upon transplantation 
(Cicalese, Bonizzi et al. 2009). Notably, PKHneg cells, as compared to PKHhigh, do not 
express many genes specific for the mammary SCs (Lim, Wu et al. 2010, Soady, Kendrick 
et al. 2015), including CD24, epcam, jag1, dll1, Apoe, Id4, Erg, Krt5, Krt14, grik3, Ift57, 
Ltbp2, Mllt3, Nfatc2, Ngfr, Ppp1r14a, scube3, Stk39, Tm6sf1, cdh5, Pdgfb, Ptprb, Ptprz1 
(data not shown; obtained from RNAseq analyses of PKHhigh and PKHneg from WT 
mammosphere cultures). 
To investigate if Myc can confer SC-like behavior onto more differentiated progenitors we 
employed the Rosa26-MycER transgenic model. Therefore, we sorted the population that 
had not retained the PKH26 dye after one week of labeling and plated the cells in 
anchorage independent conditions in order to favor mammosphere formation (Figure 
4-27). As expected, PKHneg cells not treated with 4-OHT rapidly exhausted after few 
passages (GR=-73.7%), thus confirming that they consist of short living progenitors with 
limited self-renewal capacity. On the contrary, PKHneg cells treated with low-dose 4-OHT 
indefinitely extend their replating potential, thus implying the acquisition of unlimited self-
renewal potential (Figure 4-28). This was mirrored, as previously observed for the bulk 
mammosphere culture, by an increase in the size and cumulative cell number of 4-OHT-
treated spheres, as compared to the untreated cells (UT), which indicates acquisition of 
greater replicative potential (Figure 4-29).  
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Figure 4-27: Schematic representation of the PKH-26 assay. 
Rosa26-MycER HE cells were plated in mammosphere culture and labeled with PKH-26 dye for one week. 
Cells that did not retain the dye (PKHneg) were sorted at FACS and re-plated as mammospheres in the 
presence or absence of 4-OHT for the induction of Myc. 
 
 
 
 
Figure 4-28: Growth curve of Rosa26-MycER progenitor spheres.  
Semi-logarithmic plot of Cumulative Sphere numbers. Numbers were obtained from serial replating of 
PKHneg mammary progenitors derived from Rosa26-MycER mice in the absence or continuous presence of 
two different concentrations of 4-OHT. Each dot in the curve represents the mean of three independent 
curves; error bars indicate the standard deviation. Regression analysis was performed to obtain trend lines 
(dashed lines) that best approximate the curves. Growth rates (GR) and coefficients of determination (R2) for 
each trend line are reported inside the graph. 
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Figure 4-29: Growth curve of Rosa26-MycER progenitor cells. 
Semi-logarithmic plot of Cumulative Cell numbers. Numbers were obtained from serial replating of PKHneg 
mammary progenitors derived from Rosa26-MycER mice in the absence or continuous presence of the two 
different concentrations of 4-OHT. Each dot in the curve represents the mean of three independent curves; 
error bars indicate the standard deviation. Regression analysis was performed to obtain trend lines (dashed 
lines) that best approximate the curves. Growth rates (GR) and coefficients of determination (R2) for each 
trend line are reported inside the graph. 
 
4.3.2 Effect	  of	  Myc	  on	  the	  ability	  of	  mammary	  progenitors	  to	  reconstitute	  a	  mammary	  
gland	  tissue	  
 
To investigate whether Myc-expressing progenitors are able to differentiate into all the cell 
types that compose the mammary gland, we transduced PKHneg cells with the MycER 
vector and transplanted them under limiting dilution conditions into the cleared fat-pad of 
pre-pubertal recipient mice. The mice were sacrificed after 12 weeks and their inguinal 
mammary glands collected for whole mount staining to evaluate the presence of positive 
outgrowths (DeOme, Faulkin et al. 1959). Strikingly, PKHneg cells expressing MycER 
were able to give rise to complete outhgrowths with a calculated SC frequency of around 
Chapter	  4.3	  -­‐	  Results	  
 82 
1:100,000 (Table 4-2, Figure 4-30), while PKHneg progenitors transduced with the empty 
vector never reconstituted the gland in the cleared fat pad. This suggests that low levels of 
Myc can reprogram progenitors into bona fide SCs, e.g. cells with repopulating ability, 
albeit at a low frequency.  
 
 
 
Table 4-2: Limiting dilution transplantation experiment of PKHneg progenitors transduced with 
Empty vector or MycER. 
Cells suspension from PKHneg progenitors infected with Empty or MycER vector were inoculated in 
recipient mice in limiting dilution conditions (from 100,000 to 5,000 cells). Results show the number of 
positive outgrowths as defined by the presence of epithelial structures with radial organization in stained 
whole mounts 12 weeks after the injection. SC frequencies (estimates and upper/lower limits) were 
calculated by limiting dilution analysis, as described in the Materials and Methods section. Slope is a 
measure of the linearity of the limiting dilution test; its nominal value is equal to 1. Fitting to the single hit 
model is indicated by p-values >0.05. 
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Figure 4-30: Whole mount staining of a positive outgrowth resulting from the injection of PKHneg-
MycER cells. 
Representative image of carmine alum whole mount staining of a reconstituted gland after injection of 50,000 
MycER-transduced PKHneg progenitors. Scale bar as indicated.  
 
 
To investigate whether PKHneg-MycER SCs are capable of normal physiological 
differentiation in vivo, we analyzed mammary glands from six outgrowths of 50,000 
transplanted PKHneg-MycER cells, as compared to outgrowths derived from the 
transplantation of the same number of WT cells. We first tested the regenerative potential 
of PKHneg-MycER progenitors calculating the extent of mammary epithelium within the 
fat pad by digital image analysis (DIA). Results showed that the percentage of the area 
occupied by epithelial structures was around 2% in each acquired field and was in the same 
range of the value reported for outgrowths derived from WT mammospheres (Table 4-3). 
Staining for KI67, a nuclear marker of cycling cells, confirmed that the rate of proliferation 
was also comparable between the two experimental groups (Table 4-3). Analyses of 
histology of the mammary glands (on haematoxylin-eosin staining) showed some degree of 
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hyperplastic and dysplastic features in all mammary glands obtained from the PKHneg-
MycER progenitors. (Figure 4-31, HE staining).  Notably, however, when compared with 
those from four mammary-gland outgrowths arisen from WT control cells, we observed a 
similar degree of hyperplasia/dyspasia, suggesting that it is rather a consequence of active 
regeneration inherent to the transplantation procedure, not related to a process of 
transformation fired by Myc (Table 4-3). In line with this, a total of 6 mice were kept 
under observation for one year after the transplantation procedure and none of them 
displayed any palpable masses.  
 
 
Table 4-3: Histological evaluation of the outgrowths resulting from “reprogrammed” progenitor and 
WT cells. 
Outgrowths resulting from WT (n=4) and PKHneg-MycER (n=6) transplantations were stained for whole 
mount evaluation, paraffin embedded and sectioned for histopathological evaluation. To assess the extent of 
the mammary reconstitution in each examined sample, the area (µm2) occupied by the mammary epithelium 
was calculated by DIA and it is shown as percentage of the total area (mean±sd) of the field under 
examination. Anti-KI67 staining was performed; KI67 index was calculated as the ratio between KI67 
positive vs. negative cells (mean±sd) in 400X microscopic fields (four fields per sample). Histological 
grading of epithelial hyperplasia/dysplasia of ductular and alveolar epithelial structures was performed 
according to the following criteria: (++) = multifocal to diffuse moderate ductular and/or alveolar epithelial 
hypertrophy and hyperplasia, without relevant cell atypia; (+++) = focal to multifocal areas of mammary 
epithelial dysplasia with variable cell atypia 
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Differentiation capacity of the “reprogrammed” progenitors was analyzed on paraffin-
embedded slides by immunohistochemical analysis for the terminal differentiation markers 
of the mammary gland epithelial structures. The results show that the PKHneg-MycER 
transplanted glands correctly express markers for basal (K14) and luminal (K18) 
development, thus demonstrating the ability of the “reprogrammed” cells to give rise to a 
normally differentiated gland (Figure 4-31).  
 
 
Figure 4-31: “Reprogrammed” progenitors form normal differentiating tissue upon transplantations 
in vivo. 
Twelve weeks after transplant, whole mounts of outgrowths formed in the transplanted fat pads of injected 
mice were stained with carmine and then paraffin-embedded and sectioned for immuno-histochemical 
analysis. Tissue sections of samples from WT cells and PKHneg-MycER transplanted mice were then stained 
for HE evaluation of the epithelial structures (left); for basal epithelial marker K14 (middle) and for luminal 
epithelial marker K18 (right). All images were acquired with a 10X magnification objective. 
 
Finally, to test the capacity of PKHneg-MycER progenitors to generate fully functional 
mammary glands, we analyzed mammary-gland changes during pregnancy. Therefore, 10 
weeks after the injection of 50,000 PKHneg-MycER cells, we mated the transplanted mice 
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with control male mice and analyzed mammary glands at day 18.5 of pregnancy for the 
presence of milk, by staining whole mounts for beta-casein.  
All the glands under analysis (n=5) resulted positive for beta-casein staining and to the 
same extent of not transplanted pregnant control animals (Figure 4-32), thus indicating 
that the transplanted glands are able to fully differentiate into a completely functional 
tissue.  
 
 
Figure 4-32: “Reprogrammed” progenitors form functional tissue upon transplantations in vivo. 
Female mice were transplanted with PKHneg-MycER cells, successfully mated, and outgrowths collected at 
day 18.5 of pregnancy. The glands were stained with carmine for whole mount evaluation and then paraffin-
embedded and sectioned for immuno-histochemical analysis. Tissue sections were stained for hematoxilin-
eosin (H&E) evaluation of the epithelial structures (left) and for beta-casein as a marker of the presence of 
milk in the alveolar buds. All images were acquired with a 20X magnification objective. 
 
 
4.3.3 Myc	  reprograms	  mammary	  progenitors	  into	  long	  living	  stem	  cells	  
 
Finally, we investigated the in vivo self-renewal properties of PKHneg-MycER 
progenitors, by the serial transplantation assay, which unequivocally proves the existence 
of long living SCs in a given population.  
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To perform serial transplantation assay of the PKHneg-MycER progenitors we took 
advantage of a GFP transgenic mouse model that allowed us to track the transplanted cells. 
We transduced with MycER vector the PKHneg cells derived from this model and we 
performed the first transplantation experiment (P1 in Figure 4-33). Twelve weeks later, we 
collected the glands and performed FACS-sorting of the GFP positive cells. These were 
then re-transplanted in the cleared fat pad of new recipients and positive outgrowths were 
scored 12 weeks later. As shown in Table 4-4, 2 out of 8 glands resulted positive to whole 
mount evaluation and, notably, their epithelial structures were positive to anti-GFP 
staining, thus confirming their derivation from the original “reprogrammed” population 
(P2, Figure 4-33). Furthermore, the predicted SC frequency of the secondary transplants 
(1:2607) is in line with the frequencies reported for total epithelial cell transplantations 
(Cicalese, Bonizzi et al. 2009), thus strengthening the concept of reconstitution of a 
completely normal gland upon transplantation of MycER transduced progenitors.  
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Figure 4-33: Serial transplantation of positive outgrowth. 
TOP: Description of the experiment. Female mice were transplanted with 50,000 PKHneg-MycER cells 
derived from GFP-FVB mice, and glands collected 12 weeks after the injection (P1). The presence of 
positive outgrowths was scored with whole mount staining and IHC analysis of GFP expression (bottom). 
GFP positive cells from a pooled group of 8 glands were sorted by FACS and re-transplanted in 8 recipient 
mice. 12 weeks after, the presence of positive outgrowths was scored with whole mount staining and IHC 
analysis of GFP expression (P2, bottom).   
 
 
 
Table 4-4: Efficiency of serial transplantation.  
750 GFP+ total epithelial cells derived from P1 transplanted mice were re-transplanted into the cleared fat 
pad of 8 recipient mice. SC frequencies (estimates and upper/lower limits) were calculated by limiting 
dilution analysis, as described in the Materials and Methods section.   
 
 
To summarize, we have shown that low levels of Myc expression in mammary progenitors: 
1) confer on them mammosphere initiating potential; 2) endow them with reconstitution 
ability; 3) reconstitute a gland that is morphologically normal and fully functional; 4) 
generate true SCs able to survive upon serial transplantation. All together, these data 
demonstrate that Myc is able to reprogram a heterogeneous population of committed 
progenitors into bona fide SCs (albeit at low frequency).  
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Thus reprogramming might represent, together with the increased frequency of SC 
symmetric divisions (Pasi et al. unpublished results), one of the key mechanisms instructed 
by p53 loss and operated by Myc dysregulation that ultimately leads to the uncontrolled 
expansion of a SC-pool.  
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4.4 Myc	  expression	  alone	  is	  sufficient	  for	  the	  expansion	  of	  the	  SC	  pool	  
 
We next investigated whether constitutive Myc expression in ErbB2 tumors is the critical 
effector of p53-loss, by a reverse genetic approach.  
 
4.4.1 Depletion	  of	  Myc	  impairs	  CSCs’	  unlimited	  expansion	  
 
First, we evaluated whether suppression of Myc activity, using a Myc-specific shRNA or a 
dominant-negative Myc mutant, leads to the disruption of the “p53-loss phenotype” of 
CSCs, e.g. immortality and exponential growth (Cicalese, Bonizzi et al. 2009).  To this 
end, we infected ErbB2-tumor or WT mammospheres with a vector expressing Myc-
specific shRNAs (pLKO-c-Myc-shRNA). Myc silencing, however, resulted in a rapid and 
complete cell growth arrest of both WT and ErbB2-tumor cells, likely due to a strict Myc-
dependency of mammary epithelial cell proliferation (data not shown). As alternative 
approach, we expressed in ErbB2 mammospheres the dominant-negative mutant of Myc 
(Omomyc), which omo-dimerizes with endogenous Myc leading to its irreversible 
functional impairment (Soucek, Whitfield et al. 2008). The coding sequence for the 
Omomyc cDNA is downstream of a tetra- cycline-responsive promoter element (TRE) and 
was cloned in frame with a TurboRFP cassette in the pTRIPZ backbone, which harbors a 
TetO element ensuring Omomyc inducibility upon doxycycline administration. Once the 
tumor mammospheres had been transduced with the Omomyc construct, we induced its 
expression with two different concentrations of doxycycline (0.5 and 1 µM) and monitored 
sphere forming efficiency and replicative potential of our cells. In parallel, as a control, we 
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also induced cells transduced with the pTRIPZ empty vector. The results shown in Figure 
4-34 (right) depict the successful induction of the RFP-Omomyc fusion protein, as 
indicated by RFP positivity, and a significant drop in tumor sphere forming efficiency 
upon induction at both concentrations of doxycycline (Figure 4-34, left). This suggests 
that the presence of a functional Myc is a fundamental pre-requisite for CSC expansion in 
culture. Notably, Omomyc expression had little effect on the growth of WT 
mammospheres (data not shown). 
 
        
Figure 4-34: The expression of the pTRIPZ-Omomyc-TurboRFP vector impairs tumor sphere forming 
ability. 
LEFT: ErbB2 mammospheres transduced with the Omomyc vector or the empty backbone and treated with 
doxycycline (1µM) for one week; the efficiency of induction is indicated by the RFP signal. Spheres pictures 
were acquired at a stereomicroscope with 0.8X magnification. RIGHT: Relative sphere forming efficiency 
(SFE) of cells transduced with the empty vector or the Omomyc vector and treated for one week with 
doxycycline at the indicated concentrations (untreated spheres of each group =1). 
 
 
Additionally, qPCR of two known Myc targets (Nucleolin and ODC1) revealed a very 
modest effect of Omomyc expression on Myc transcriptional activity (Figure 4-35), 
suggesting that pTRIPZ-Omomyc vector does not allow high levels of expression of 
Omomyc in our cell system. Possibly this is why its expression is compatible with cell 
viability, in contrast with what we observed with Myc-shRNA.  
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Figure 4-35:  mRNA expression of Myc target genes upon Omomyc induction. 
qPCR analysis of two known Myc target genes (NCL and ODC1) in empty vector or Omomyc transduced 
spheres. Induction was performed with two concentration of doxycycline (0.5 and 1 µM) for 72 hours. For 
each experimental group, values are normalized against the qPCR data of untreated spheres (UT=1). 
 
Collectively, these data demonstrate that inhibition of Myc in mammary epithelial cells 
leads to an impairment of the sphere forming ability of CSCs, thus highlighting its 
fundamental role in the maintenance of cell growth and viability. However, this approach 
did not allow asking the question as to whether Myc constitutive expression alone is 
sufficient to maintain the increased self-renewal in the ErbB2-tumor CSCs. 
 
4.4.2 Uncoupling	  the	  p53:Myc	  axis	  
 
As a complementary approach, we tried to uncouple the p53:Myc axis, in order to 
investigate the effects of myc on CSCs independently of the loss of function of p53. 
Restoration of p53 signaling in ErbB2 mammospheres has the effect of re-establishing the 
balance between SC asymmetric and symmetric divisions, thus leading to the gradual 
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functional exhaustion of mammosphere initiating cells in culture and, more generally, 
depletion of the content in CSCs, as demonstrated by limiting dilution transplantations in 
vivo (Cicalese, Bonizzi et al. 2009). We now know that this effect happens concomitantly 
with the down regulation of Myc protein and mRNA levels upon Nutlin treatment (see 
section 4.1.2). To uncouple the p53 and Myc pathways, we first enforced the Myc 
expression in the ErbB2-tumor mammospheres, by transducing them with the MycER 
lentiviral vector. Then, we restored levels of p53 in the MycER-expressing tumor 
mammospheres by treating them with Nutlin-3, as described in section 4.1.2. In this 
scenario, we can analyze the effect of constitutive Myc expression on CSCs in the presence 
of functional p53. 
Strikingly, results show that, while the treatment with one dose of Nutlin has the effect of 
slowing down the growth of tumor mammospheres transduced with the empty vector, as 
expected (GR=76%), the presence of MycER renders the restoration of p53 ineffective and 
leads to a complete rescue of the CSC phenotype, as indicated by the fact that the spheres 
show typical CSC unlimited exponential growth (GR=196%) in culture (Figure 4-36). In 
line with this, the cumulative number of cells in culture (replicative potential) also remains 
unaffected by Nutlin administration when Myc is constitutively expressed (Figure 4-37). 
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Figure 4-36: ErbB2 mammospheres transduced with MycER are rescued from the Nutlin effect. 
Semi-logarithmic plot of Cumulative Sphere numbers. Numbers were obtained from serial replating of 
MMTV-ErbB2 mammospheres, transduced with empty or MycER vector, in the absence or continuous 
presence of Nutlin-3 (2.5µM). Each dot in the curve represents the mean of three independent curves; error 
bars indicate the standard deviation. Regression analysis was performed to obtain trend lines (dashed lines) 
that best approximate the curves. Growth rates (GR) and coefficients of determination (R2) for each trend line 
are reported inside the graph. 
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Figure 4-37: Cumulative cell number of ErbB2 mammospheres transduced with MycER and rescued 
from the Nutlin effect. 
Semi-logarithmic plot of Cumulative Cell number. Numbers were obtained from disaggregation to single 
cells of MMTV-ErbB2 mammospheres, transduced with empty or MycER vector, in the absence or 
continuous presence of Nutlin-3 (2.5µM). Each dot in the curve represents the mean of three independent 
curves; error bars indicate the standard deviation. Regression analysis was performed to obtain trend lines 
(dashed lines) that best approximate the curves. Growth rates (GR) and coefficients of determination (R2) for 
each trend line are reported inside the graph. 
 
 
Thus, in the context of the enforced expression of Myc, restoration of p53 function in 
tumor mammospheres is not sufficient, by itself, to prevent CSC expansion, suggesting 
that: 1) Myc acts downstream of p53 and 2) Myc is the critical key effector of CSC 
maintenance. 
To validate these findings in vivo, we transplanted ErbB2 tumor cells, infected with either 
MycER or its corresponding empty vector, in a total of 25 recipient mice; then, when the 
tumors were palpable (tumor volume ≈ 100 mm3), we divided the cohort of mice in two 
further groups: those to be treated with Nutlin-3 (20 mg/kg of body weight) and those to be 
treated with the treatment vehicle (DMSO). The treatment consisted of seven IP injections 
every other day for a total period of 14 days. At the end of it, we measured the volume of 
the resulting tumors: while for the Empty vector-transplanted cohort the Nutlin treatment 
effectively led to a reduction in tumor size, as compared to the vehicle treated cohort, the 
same was not true for the MycER-transplanted cohort. In this experimental group, in fact, 
all the tumors grew at the same rate, regardless of the administration of Nutlin (Figure 
4-38). Therefore, the in vivo data mirror the growth behavior we observed in the 
mammosphere cultures, with MycER expression being able, by itself, to maintain cancer 
expansion, independently of p53 functionality. 
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Figure 4-38: Nutlin treatment does not affect the growth of MycER expressing tumors. 
Mice were transplanted with ErbB2 cells transduced with the Empty (n=13) or the MycER (n=12) vector. At 
the time of palpability (tumor volume ≤ 100mm3) the mice of each group were treated with DMSO (VEH; 
n=7 for Empty and n=6 for MycER) or with Nutlin-3 (NUT: 20 mg/Kg, n=6 for both Empty and MycER). 
Tumor volume was measured at the end of the 2 weeks of treatment. 
 
All together these data suggest that attenuated p53 function, which is a common event in 
many types of tumors, including breast cancer, has profound effects on a cancer population 
that has the features of CSCs by acting through the de-regulation of its downstream 
effector Myc. De-regulated Myc is able by itself to fuel the maintenance of the cancer 
clone, most likely by the rewiring of SC-like mechanisms that ultimately sustain cancer 
development and progression.   
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4.5 Downstream	  of	  the	  p53:Myc	  axis	  
 
A further question we have been trying to answer with this thesis work is which 
intracellular pathway is directly instructed by the p53:Myc axis and is responsible of the 
biological processes we have described. To address this issue we took advantage of the 
genome-wide expression data derived from the previously described RNAseq datasets (see 
section 4.1.4).  
In summary, we have generated 4 relevant datasets of differentially expressed genes 
(DEGs): i) genes that are deregulated by oncogene expression in mammary tumor cells 
(obtained by comparing RNAseq data from ErbB2-tumor vs. WT mammospheres); ii) 
genes that are regulated by p53 expression in mammary normal cells (obtained by 
comparing RNAseq data from p53-/- vs. WT mammospheres); iii) genes that are de-
regulated by constitutive Myc expression in mammary cells (obtained by comparing 
RNAseq data from Myc-ER-expressing and control WT mammospheres); and iv) genes 
that are deregulated in tumor cells as a consequence of p53-loss (obtained by comparing 
RNAseq data from non-treated ErbB2-tumor vs. Nutlin-treated tumor mammospheres). For 
all these dataset, we applied stringent conditions of comparative analyses, setting a cut-off 
on the q-value (≤ 0.05) and on the log2fold change (log2FC = |1|) (Table 4-5).  
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Table 4-5: Differentially expressed genes (DEGs) in selected RNAseq datasets. 
Number of DEGs in each of the indicated comparisons among cell types that satisfy the following thresholds: 
q value equal or lower than 0.05; Log2FC = |1|. Total: total number of DEGs per group; UP: up-regulated 
genes; DOWN: down-regulated genes. The last row indicates the total number of non-redundant genes 
among all the experimental groups. 
 
 
To identify p53:Myc dependent genes in the erbB2 tumors, we searched for genes in 
common among the four datasets. Strikingly, from a total of 5,236 non-redundant DEGs 
present in the 4 datasets, comparative analyses revealed 140 DEGs, including 136 up-
regulated genes and 4 down-regulated genes (Figure 4-39). Thus, the ErbB2 tumors are 
characterized by 140 genes whose de-regulated expression depends on ErbB2, p53-loss 
and constitutive Myc expression, which should represent the downstream effectors of the 
deregulated p53:Myc axis in mammary cancer cells. 
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Figure 4-39: Intercrosses among the four datasets generated by RNAseq.  
Venn diagrams show the overlap among the UP regulated and DOWN regulated genes in each of the four 
datasets under analysis (ErbB2 vs. WT; p53-/- vs. WT; MycER vs. WT; ErbB2 vs ErbB2+NUT) 
 
To investigate which cellular processes might be affected by the identified 140 DEGs, we 
then performed a pathway analysis and gene ontology (GO) search, taking advantage of the 
molecular signature database (MSigDB) available on the GSEA website 
(www.broadinstitute.org/gsea). In details, we computed the overlap between our gene-set 
and curated gene datasets (C2) which consist of a collection of various databases, such as 
online pathway databases, including KEGG, BIOCARTA and REACTOME, and 
knowledge of domain experts. In Table 4-6 the top 20 pathways are listed together with 
the number of genes, among the 140, in overlap with a given dataset. Remarkably, all the 
pathways we found are cell cycle related, with a particular focus on mitotic processes. As a 
visual aid, the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway named “Cell-
Cycle” is shown in Figure 4-40, and the genes present in our list are highlighted with a red 
star. As it is clear from the figures, most of these genes are key component of the G2/M 
and mitotic processes. 
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Table 4-6: Pathway analysis of the 140 genes in our signature. 
Computed overlap between our signature and curated gene signatures performed through the C2 tool 
(www.broadinstitute.org/gsea). The top 20 pathways are shown under the Gene set name. # Genes in the gene 
set (K): total number of genes in the called dataset; # Genes in overlap (k): number of genes of our signature 
that overlap with those of the called dataset; k/K: ratio of the genes in overlap with the total number of genes 
of the called dataset. 
 
 
Chapter	  4.5	  -­‐	  Results	  
 101 
 
Figure 4-40: KEGG pathway: cell cycle. 
Representative image of the KEGG cell cycle pathway as depicted by DAVID (the Database 
for Annotation, Visualization and Integrated Discovery) bioinformatics tool. Red stars indicate the genes 
present in our signature 
 
 
Furthermore, when we performed a GO analysis (C5), in which the overlap between our 
dataset and annotated genes based on their ontology (biological processes, cellular 
component, molecular function), we could again observe an enrichment of cell cycle and 
mitosis-specifically-related terms (listed in Table 4-7).  
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Table 4-7: Gene Ontology analysis of our gene signature. 
Computed overlap between our signature and genes annotated by their ontology, performed through the C5 
tool (www.broadinstitute.org/gsea). The top 20 GO terms are shown under the Gene set name. # Genes in the 
gene set (K): total number of genes in the called GO term; # Genes in overlap (k): number of genes of our 
signature that overlap with those of the called GO term; k/K: ratio of the genes in overlap with the total 
number of genes of the called GO term. 
 
 
More in details, the list enrolls a total of 82 genes related to mitosis. Functionally, 
expression of all these genes is required for: the APC/C mediated mitotic spindle 
checkpoint (Bub1, Bub1B, Mad2l1, cdc20) that is activated by mis-attachment of 
microtubules and sister-chromatids to kinetochores, and delays mitosis until all 
kinetochores are properly attached; the G2/M checkpoint (Cdc45, Cdc25c, Mcm5/6/8/10, 
Chek1); mitosis-entry or progression (Cdk1, cyclinA and B1, CDC25A/B, Plk1, 
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AuroraA/B, Nek2, Plk1/4); spindle assembly at metaphase (AurkA, AurkB, Plk1, Nek2); 
association to kinetochore complexes (CenpH/I/Q/M/N, Nls1, Nuf2, Kntc1). Furthermore 
the list includes the M-phase promoting factor Cdk1-Ccnb1 and many genes involved in 
the assembly and motility of the spindle microtubules, like Kif2c, Kif18a, Kif20a, 
Racgap1. 
 
Taken together, it emerges from these data that our p53-Myc dependent signature in 
tumors is enriched for genes involved in the process of mitosis and cytokinesis, suggesting 
that the p53:Myc axis could exert its tumor suppressive role by tightly regulating cell 
division mechanisms, in terms of organization of the mitotic spindle, regulation of 
cytoskeleton changes, and distribution of the organelles.  
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5 Discussion	  
5.1 Epistatic	  relationship	  between	  p53	  and	  Myc	  in	  mammary	  SCs	  and	  CSCs	  
 
The CSC population is defined as the rare population of cells which maintain the cancer 
clone and sustain its progression and its recurrence after chemotherapy. CSCs share many 
properties with normal SCs, including the ability to regenerate (self-renewal) and the 
capacity to form differentially specialized progeny. These two properties can be 
accomplished at the same time by a peculiar type of mitosis, the asymmetric cell division, 
whereby one SC gives rise to two daughter cells: one committed toward differentiation, the 
other maintaining SC identity. In situations requiring tissue regeneration, SCs can also 
divide symmetrically, generating two identical daughter cells endowed with the same self-
renewal potential of the mother. 
These two modalities of division, symmetric and asymmetric, are tightly regulated in 
normal tissues and allow maintenance of constant numbers of SCs under homeostatic 
conditions. SCs mode of division is one of the cellular processes that are altered in CSCs 
and that promote their transformation. Our group demonstrated that a switch from 
asymmetric to symmetric SC division is the underlying force determining CSC unlimited 
expansion in a model of breast tumorigenesis. The growth and self-renewal properties of 
CSCs were modeled with in vitro (i.e., via the ability of SCs and CSCs to form 
mammospheres that could be propagated in culture) and in vivo (i.e., via the ability to 
repopulate the cleared fat-pad of a mouse and develop into normal tissues or tumors with 
the same complexity of the tissues of origin) assays. They led to the observation that CSCs 
constantly expand, both in vitro and in vivo, and thus have increased replicative potential. 
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The tumor suppressor gene p53 was found to be the master regulator governing the choice 
between symmetry and asymmetry at SC mitosis, and its absence or functional impairment 
was demonstrated to be the leading cause of CSC extended self-renewal. Moreover, 
restoration of p53 signaling by Nutlin-3 administration in tumors was shown to re-assess 
the balance between symmetric and asymmetric divisions and, consequently, set a brake on 
the geometric growth of CSCs and reduce their total number, as demonstrated by 
transplantation experiments (Cicalese, Bonizzi et al. 2009). 
Being p53 at the center of a plethora of regulatory networks that go from DNA damage 
response to cell cycle arrest, we wanted to understand which one is the relevant 
downstream pathway in the described biological phenotype. 
To this end, we used a candidate gene approach and investigated Myc as the putative 
downstream effector of p53. Myc is frequently de-regulated in cancer and is also a key 
player in SC biology. Its transcriptional program has been linked to SC-like signatures and 
is found enriched in the more aggressive, metastatic and poorly differentiated breast 
cancers (Kim, Woo et al. 2010); furthermore, Myc is a known key gene in the maintenance 
of the pluripotent state in ESCs. Of note, Myc expression is repressed by p53 (Ho, Ma et 
al. 2005, Sachdeva, Zhu et al. 2009, Li, He et al. 2012).  
In line with our hypothesis, we found that both Myc levels and Myc transcriptional activity 
are up-regulated and de-regulated in our ErbB2 driven tumor model of mammary gland 
carcinogenesis. In this model, a constitutively active ErbB2 affects the regulation of 
Mdm2, an E3 ubiquitin-ligase which targets p53 for degradation, by activating the Akt 
pathway that, in turn, enhances Mdm2 phosphorylation and therefore inhibits p53 
functions (Zhou, Liao et al. 2001). We have shown that the treatment of MMTV-ErbB2 
mammospheres with the Mdm-2 inhibitor Nutlin-3 and the consequent disruption of the 
p53-degrading pathway result in the down-regulation of Myc both at the mRNA and at the 
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protein level. Our data, derived from p53-/- and p53+/- models and from acute activation 
of p53, suggest that p53 and Myc are epistatically related, with the first molecule actively 
repressing the second. These results contribute to add complexity to the intricate network 
involving these two master regulators of transcription in the cell. It is also very well 
known, in fact, that over-expression of Myc leads to p53-dependent induction of apoptosis 
(Hermeking and Eick 1994). This notion found confirmation in previous data from our 
group showing that high levels of Myc lead to p53 mediated apoptotic death (Pasi, Dereli-
Oz et al. 2011). Together these findings suggest that a tight regulation of the interaction 
between p53 and Myc in a cell is essential to determine its destiny and that any change in 
the levels of these two molecules could lead to important, and different, biological outputs. 
In this thesis, we envision a model in which the loss of function of p53 impacts on the fine 
regulation of Myc, which, once de-regulated, is the key effector of the biological processes 
that alter SC functions. Whether this regulation is direct or indirect remains still unknown, 
although we have indication that a transcriptional mechanism could be involved. Indeed, 
we have shown that Myc mRNA abundance is strongly dependent on the levels of p53. 
When we examined Myc expression in non-transformed mammospheres harboring the 
homozygous or hemizygous knock-out of the p53 allele, the levels of Myc transcript were 
varying coherently; furthermore, the acute activation of p53 upon Adriamycin treatment of 
WT cells profoundly down-regulated Myc at the transcriptional level. Preliminary data 
based on ChIP-qPCR experiments on a murine immortalized mammary cell line, 
confirmed that high levels of p53 lead to its recruitment on the Myc promoter. 
Nevertheless, considering also that there are many controversies around the mechanisms of 
trans-repression by p53, we cannot exclude that additional post-transcriptional regulation is 
taking place in the peculiar phenotype we describe. Indeed, in the context of somatic cell 
reprogramming to ESCs and tissue de-differentiation, it is known that p53 can “put a 
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brake” on SCs through the activation of specific families of miRNAs, such as miR-34, 
miR-145, and miR146, which are involved in numerous inhibitory activities of SC self-
renewal (Bieging, Mello et al. 2014). In particular, the miR-145 family has been shown to 
negatively regulate Myc (Sachdeva, Zhu et al. 2009), while miR-34 is predicted to bind 
Myc 3’-UTR sequence (our unpublished observations). Both transcriptional and post-
transcriptional mechanisms of regulation are concordant with the fact that exogenous 
MycER expression is not controlled by p53 in our system, as this human coding sequence 
does not possess the Myc-3’UTR. Therefore, it seems plausible that p53 exerts its control 
on Myc through multiple mechanisms, according to the complex upstream signaling 
network that carefully regulates the levels of Myc in the cell. 
 
5.2 The	  p53:Myc	  axis	  in	  the	  self-­‐renewal	  of	  mammary	  SCs	  
 
The tight regulation of Myc expression is a key tumor suppressive mechanism. Indeed, it is 
evident from both our data and published studies that too little or too much Myc is harmful 
to a cell; this is why its levels and its activity are so stringently controlled by multiple 
mechanisms and restrained by feedback loops. Our results show that the over-expression of 
Myc leads to very different outcomes, depending on the extent of its activation: in our 
studies, both mammary SCs and progenitor cells composing the mammospheres responded 
either by activating an apoptotic response (high level up-regulation) or by intensifying their 
self-renewal (low level increase). Conversely, too little Myc was shown to be extremely 
deleterious for mammary SCs, as infection with a Myc-targeting shRNA was not 
compatible with cell survival. Only when we impaired Myc functions through the 
exogenous expression of low levels of a Myc dominant-negative mutant (Omomyc), we 
managed to observe a reduction in the CSCs’ sphere-forming ability. Notably, preliminary 
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observations suggest that Omomyc expression does not induce toxicity to WT 
mammosphere cultures. All together, these observations indicate that a precise regulation 
of the amount of the Myc protein and its concomitant signaling are important factors in the 
control of mammary stem and progenitor cell fate decisions. Clearly, in cancer, these 
regulatory networks are altered and Myc is found de-regulated in a very high fraction of 
human tumors. 
In line with this, Myc is found over-expressed and de-regulated in our model of breast 
tumorigenesis. Indeed we have shown both ex vivo and in vitro that ErbB2 tumors display 
higher levels of the Myc protein and Myc mRNA than WT mammary glands. Furthermore, 
these levels remain constantly high during mammosphere formation, while WT cells stop 
proliferating and down-regulate Myc expression. Remarkably, Myc transcriptional activity 
mirrors this behavior, thus showing that a Myc-dependent gene signature is active in our 
ErbB2-driven tumors. 
In our system, over-expression of Myc did not transform normal SCs, as transplantation of 
cells transduced with the MycER vector into recipient mice resulted in the formation of 
normal tissues two months after engraftment, and in the absence of palpable masses up to 
one year after the injection. This is in accordance with what is known in the literature: Myc 
alone can initiate tumorigenesis but needs cooperating events to induce a full-blown 
transformed phenotype (Gabay, Li et al. 2014). Therefore, it is reasonable to hypothesize 
that tumor formation in low Myc-expressing cells does not occur, even after a very long 
latency, until these cells undergo a second oncogenic hit. 
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5.2.1 Dissecting	  the	  p53:Myc	  axis	  in	  stem	  and	  progenitor	  cells	  
 
We have shown that precise de-regulation of the levels of Myc induces profound changes 
in the balance between self-renewal and differentiation. Indeed, the number of SCs within 
a mammosphere culture appears to increase upon enforced expression of Myc, as 
demonstrated by mammosphere assays and by transplantation in the cleared fat pad. We 
showed that this effect can be explained by two mechanisms: on the SCs’ side, low-Myc 
promotes switching of the modality of division of purified SCs, from mainly asymmetric to 
mainly symmetric; on the progenitors’ side, it induces phenotypic changes that bestow 
them a new identity, with properties and functions that usually define SCs. To be able to 
dissect the two mechanisms, we purified a population enriched in SCs (Cicalese, Bonizzi et 
al. 2009), which was slowly proliferating and therefore retaining the PKH-26 dye, as 
opposed to the putative progenitor population (PKHneg).  
PKHneg cells in fact do not contain cells with SC properties as they i) are not able to form 
clonal mammospheres in culture, but only small and irregular aggregates that cannot be 
passaged; ii) can only form mono-lineage colonies in matrigel assays, and, most 
importantly, iii) do not reconstitute the mammary gland structure upon transplantation in 
pre-pubertal mice. However, we have demonstrated that PKHneg cells expressing low 
levels of Myc possess increased self-renewal ability in culture. Strikingly, they fully 
recapitulate the mammary gland morphogenesis and function when transplanted in the 
cleared fat pad (as demonstrated by the presence of myoepithelial and luminal cytokeratins 
and by the ability to produce milk during pregnancy), and possess high self-renewal 
potential (as suggested by serial transplantation), thus proving that they contain multipotent 
SCs. These acquired regenerative potential and self-renewing abilities suggest therefore 
Discussion	  
 110 
that progenitor cells can undergo a cellular reprogramming that leads to the formation of 
SCs.  
The reprogramming event driven by Myc happens at a very low frequency (1:100,000 
progenitors), indicating that only a few cells within this heterogeneous population of 
PKHneg cells respond to low-Myc levels and de-differentiate. This could be interpreted in 
two ways: i) the reprogramming phenomenon is completely stochastic and randomly 
targets only few cells that have a permissive genetic or epigenetic state; or ii) there exist 
preferential target populations, sharing a particular replicative history or degree of 
differentiation, which are more prone to the “low-Myc” effect. Both scenarios are plausible 
as it was demonstrated that enforced expression of Myc can have profoundly diverse 
effects depending on the differentiation stage of a cell (Wilson, Murphy et al. 2004, Watt, 
Frye et al. 2008, Reavie, Della Gatta et al. 2010), and that the epigenetic state of a cell 
influences the degree of availability of the target genes to the binding by Myc. Recent 
findings that assign to Myc a role as a general amplifier of previously activated gene 
expression programs could provide the mechanistic basis for the described heterogeneous 
responses (Lin, Lovén et al. 2012, Nie, Hu et al. 2012). 
Despite being very infrequent, this reprogramming effect is likely to have dramatic effects 
in vivo if one considers the large quantity of progenitors, at different differentiation stages, 
which reside in a tissue. 
Finally, as regards the effects of Myc on the SC population, we showed that while normal 
SCs mainly divide asymmetrically, cells with enforced expression of Myc switch to the 
symmetric mode of division. Indeed, purified PKH positive (PKHpos) cells infected with 
the MycER vector preferentially underwent symmetric divisions, generating two cells with 
analogous proliferating capacities. This was also confirmed by staining the dividing SCs 
with an antibody that recognizes the fate determinant Numb and finding that it was 
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asymmetrically distributed in WT SCs, while uniformly localized on the membrane of 
dividing SCs that expressed low levels of Myc (unpublished data). Interestingly, Numb 
was reported to be regulating the activity of p53 (Colaluca, Tosoni et al. 2008), therefore 
acting as a potential upstream link to the p53:Myc axis in the regulation of SC mitosis. 
Notably, the effect of Myc on symmetric/asymmetric divisions is undistinguishable from 
that previously described for p53-loss (Cicalese, Bonizzi et al. 2009). 
Regardless of their relative impact, the different effects of Myc on SCs and progenitors 
may contribute to the maintenance, in vivo, of the expanding pool of CSCs. We have 
shown, indeed, that Myc constitutive expression in ErbB2 tumors renders cells resistant to 
the effect of Nutlin treatment, thus demonstrating that Myc, by itself, is sufficient to 
maintain the pool of CSCs in vitro and in vivo, even when p53 is reactivated. 
In conclusion, by contributing to the continuous generation of new CSCs, both the above-
mentioned biological effects of Myc constitutive expression appear to participate in the 
process leading to tumor sustainment.  
 
5.2.2 Implications	  for	  the	  process	  of	  tumorigenesis	  
 
P53 and Myc have been implicated in the pathogenesis of different tumors, and their 
relevance for CSC specific mechanisms further confirms their criticality for the 
transformation process. 
Somatic mutations and/or deletion of the tp53 gene are found in almost every type of 
cancer at various rates (up to nearly 100% in high-grade serous carcinoma of the ovary) 
(Rivlin, Brosh et al. 2011). In tumors with low mutation rates, p53 is found in their 
germline configuration and it is often inactivated by genetic alterations of genes involved 
in the regulation of p53 functions. For example, many tumors, most frequently 
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hematological malignancies, exhibit amplification of the E3-ligase Mdm2, which leads to 
Mdm2 overexpression and p53 degradation, in the presence of WT p53 alleles (Kruse and 
Gu 2009). In breast cancer, p53 loss correlates with aggressiveness and un-differentiated 
subtypes (Mizuno, Spike et al. 2010). 
We have shown in this thesis that a functional p53 targets the expression of Myc, as its 
downstream effector for the regulation of SC self-renewal. Myc is one of the most studied 
proto-oncogenes. Mutations affecting the myc gene are found infrequently, and their effect 
on Myc function is not clear. Myc is translocated in Burkitt’s lymphomas, where it forms a 
fusion gene with the regulatory regions of the constant region of the genes coding for the 
immunoglobulin heavy or light chains (Boxer and Dang 2001). In breast cancer, genetic 
amplification of myc is reported for 22% of the cases collected by the TCGA consortium 
(Cancer Genome Atlas 2012). Nevertheless, Myc expression is elevated or de-regulated in 
a much higher fraction of breast tumors and is particularly associated with the most 
aggressive triple negative subtype (Cancer Genome Atlas 2012, Horiuchi, Kusdra et al. 
2012). A number of studies have demonstrated that the gene signature dictated by Myc 
does not only characterize ESCs but is also predictive of poor prognostic parameters, 
mainly defining the most un-differentiated, highly metastatic types of cancer (Ben-Porath, 
Thomson et al. 2008, Kim, Woo et al. 2010). 
Therefore, p53 loss and Myc activation appear to be integral processes that sustain tumor 
“stemness” in the vast majority of tumors. The continuous generation of cells with the 
properties of CSCs might represent an invariable property of many tumor types, likely the 
most aggressive ones, and the manipulation of the p53:Myc axis seems to constitute a 
potential tool to modulate tumor development. 
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5.3 A	  mitotic	  gene-­‐signature	  fuels	  the	  expansion	  of	  the	  CSC	  pool	  
 
Analysis of the p53:Myc downstream pathway might provide novel insights in the 
mechanisms of regulation of SCs in normal and transformed tissues. We have shown that 
the activity of the p53:Myc axis in CSCs might converge towards a small cluster of 140 
genes. Gene-ontology analysis of p53:Myc-regulated genes revealed enrichment of 82 
genes that are involved in the regulation of the G2 or mitotic phases of the cell cycle, 
namely mitosis-entry or progression and execution of the mitotic spindle checkpoint. 
Strikingly, all of them were down regulated by p53 and up regulated by Myc in normal 
mammary epithelial cells, while, in the ErbB2 tumor cells, they were all up-regulated. 
Most notably, expression of these genes in the tumor cells was strictly dependent on p53-
loss and Myc-activation (as inferred by the ErbB2-Nutlin dataset).  
Transcription from all these genes is usually repressed in G1 and activated in S-phase to 
progress to G2 and M. Our list enrolls many players of the mitotic spindle checkpoint 
which are important regulators of the cell replicative fate. Indeed, it is known that reduced 
levels of several components of the spindle checkpoint, including Bub3 and BubR1, induce 
cellular senescence (Stark and Taylor 2004). Thus, down-regulation of these genes in 
normal cells, following p53 activation (and down-regulation of Myc), would unequivocally 
lead to inhibition of cell proliferation, through a block of the G2-M transition or the mitotic 
process, or by acceleration of senescence. Vice versa, in cancer cells, loss of p53 function 
(and Myc activation) would favor mitotic entry and execution of the mitotic processes.  
Predicting the effects of the de-regulation of these genes in SCs and CSCs is much more 
challenging, as very little is known about their specific role in SCs. We know that de-
regulation of mitotic kinase activity, of regulators of the spindle assembly, and of 
cytokinesis has profound effect on the correct execution of SC asymmetric division. For 
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example, in Drosophila neuroblasts, mutations in mitotic kinases like Cdk1, Aurora A, 
Aurora B and Plk1 result in mis-localization of asymmetric markers and cell fate 
determinants, including Numb and Prospero, thus influencing the correct execution of 
mitosis and differently modulating cell polarity and the balance between asymmetric and 
symmetric cell divisions (Malumbres 2011). Furthermore, in Drosophila, mutagenesis of 
different centrosomal proteins causes impaired ACD of neural SCs and is tumorigenic in 
larval brain tissue; also, loss of astral microtubules can lead to inefficient spindle 
orientation and mis-segregation of cell-fate determinants (Castellanos, Dominguez et al. 
2008). 
With regard to reprogramming, it is known that differentiated cells are required to be 
cycling in order to better respond to the action of the four “reprogramming factors”, Myc, 
Oct4, Sox2 and Klf4, and turn into iPSCs. Indeed, pluripotent SCs have a peculiar cell 
cycle structure and spend relatively short time in G1 and most of the time in the S/G2/M 
phases of the cell cycle, a pre-requisite for inhibition of differentiation and for preservation 
of an epigenetic state with open chromatin (Singh and Dalton 2009).  
 
Regardless of how de-regulation of these mitotic genes might influence SC properties, a 
role for Myc and p53 in mitosis has been clearly demonstrated.  
P53 is known to be at the center of a regulatory network with several mitotic kinases, like 
Plk1, BubR1 and Aurora (Ha and Breuer 2012), which are all included in our signature. 
Several lines of evidence have demonstrated that, in mammalian cells, p53 takes part in 
pathways that maintain G2 arrest in response to DNA damage. In particular, it has been 
shown that activation of p53 induces transcriptional repression of many mitotic genes, 
including Cdc2, cyclin B2 and Cdc25C (Stark and Taylor 2004), which are all included in 
our list. P53 loss has been shown to favor reprogramming (Hong, Takahashi et al. 2009), 
Discussion	  
 115 
and p53 regulation of mitotic players could have a role in this process. The continuous 
proliferative state typical of ESCs halts the onset of replicative senescence, thus the 
concomitant loss of p53 does constitute an important pre-condition for reprogramming. It 
is known that upon mitotic-entry, all the transcriptional regulators dissociate from the 
genome and re-associate with chromatin only after cell division, thus establishing new 
gene expression patterns, as it happens during reprogramming (Egli, Birkhoff et al. 2008). 
The involvement of Myc in the regulation of mitotic progression is less well understood. It 
is known that Myc transcriptionally regulates Aurora kinases A and B, which are included 
in our list of mitotic genes, and whose role in tumorigenesis is an intense area of study also 
at the clinical level (Kollareddy, Zheleva et al. 2012). Furthermore, very recent works 
studying Myc inhibition point towards Myc involvement in cell mitotic proficiency. 
Annibali and colleagues describe defective mitosis and induction of mitotic catastrophe 
upon suppression of Myc activity through Omomyc, an effect that is mediated by Sae1, a 
protein involved in the SUMO pathway and implicated in the control of the mitotic 
chromosome structure, cell cycle progression, kinetochore function and cytokinesis 
(Annibali, Whitfield et al. 2014). These data demonstrate a central role of Myc in the 
regulation of mitotic programs, even though the precise molecular mechanisms through 
which it works are still only partially delineated, and could possibly vary among cell types 
and cell-cycle states. Additionally, enforced Myc expression might be relevant for keeping 
cells in a high rate of cycling, thus favoring the reprogramming process (Singh and Dalton 
2009). Therefore, we could speculate that by enforcing the transit through G2/M, Myc and 
the loss of p53 establish the conditions that allow the association of transcriptional 
regulators and chromatin remodelers to the genome, determining the fate of a cell at the 
onset of the new G1. 
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The molecular mechanism through which the p53:Myc axis regulates mitotic genes is 
unknown. A number of indirect data suggests that a subset of them, including those that 
came out of our analysis, shares common regulatory motifs in their promoter region that 
allow p53-mediated trans-repression. Indeed, several mitotic genes are characterized by the 
presence, in their promoters, of tandem repressor-elements (CDE/CHR) responsible for 
G1-specific silencing, namely the cell cycle-dependent element (CDE) and the cell cycle 
genes homology region (CHR).  
Many CDE⁄CHR genes, such as Cdc2, Cyclin B1, Cyclin B2 and Cdc25C, are down-
regulated by the tumor suppressor p53. The mechanisms of p53 recruitment to promoters 
of repressed target genes are not definitively ascertained. It was reported that, upon DNA 
damage, p53 binding to these promoters does not require canonical p53 binding-sites and 
depends on intact CDE/CHR/ elements (Muller and Engeland 2010). 
How Myc interacts and activates these promoters is less clear. Usually the CDE/CHR 
promoters also contain a site for transcriptional activation; indeed, they are frequently 
found in conjunction with two or three CCAAT-box elements through which NF-Y 
transcription factors activate the promoters. Thus, it is tempting to speculate that Myc is 
recruited to the CAAT-box elements at the G1-S transition, thus allowing their 
transcriptional activation during G2 and M. This would lead to envision a model in which 
these mitotic genes are directly repressed by p53 and activated by Myc by alternative 
binding to their promoters, and where p53 and Myc are epistatically related, thus providing 
coordinated repressing or activating signals in G0/G1 (by p53) and in S-G2-M (by Myc).  
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5.4 Clinical	  relevance	  
 
The p53:Myc axis might represent a critical target for anti cancer therapeutic strategies. 
Patients with tumors carrying WT p53 can be treated with drugs that reactivate p53 
function. Nutlin-3 is a small molecule that inhibits the binding between Mdm2 and p53 and 
it is currently being tested in phase I of clinical trials, together with other compounds that 
exploit the inhibition of the same catalytic pocket. Clearly, to be effective, these p53 
activators require the existence of a WT p53 as mutations in the p53 gene mainly disrupt 
its ability to bind Mdm2 (Moll and Petrenko 2003). The possibility of re-expressing p53 in 
tumors is a very promising area of therapeutics, not only because it results in an apoptotic 
or senescent response and enhancement of immune-mediated activity (Suzuki and 
Matsubara 2011), but also because it reduces the tumor mass by acting on CSCs (Cicalese, 
Bonizzi et al. 2009).  
Our experiments, both in vitro and in vivo, show that the impossibility to restore p53 
functions, due, for example, to the presence of a mutated p53, makes the tumor dependent 
on the levels of the de-regulated Myc. In line with this, it was shown that a mutant p53 
(p53-143A) binds Myc and activates its transcription, leading to Myc de-regulation 
(Frazier, He et al. 1998). “Addiction” to the “correct” levels of Myc is a common feature 
of cancer, especially of cancers driven by oncogenes other than Myc (Gabay, Li et al. 
2014), exactly like in our ErbB2 model of breast tumorigenesis. This provides relevant 
opportunities for therapy, as the suppression of Myc would efficiently promote tumor 
regression and, eventually, eradication. Currently, several strategies have been developed 
for the inhibition of Myc activity; they are either focused on inhibiting Myc expression or 
Myc ability to interact with its DNA-binding partner Max (as Omomyc does), or they 
interfere with Myc target genes. BET-bromodomain inhibitors fall in the first category 
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(Filippakopoulos, Qi et al. 2010). It has been shown that these domains are potent 
regulators of myc transcription in different tumors and the use of these inhibitors led to 
regression of multiple myeloma (Delmore, Issa et al. 2011) and acute myeloid leukemia 
(Zuber, Shi et al. 2011) in murine models. 
Omomyc was shown to be able to revert KRas-induced lung cancers and human gliomas 
without apparent toxic effects to the normal tissues (Soucek, Whitfield et al. 2013, 
Annibali, Whitfield et al. 2014). Indeed, in the in vitro testing of the efficiency of Omomyc 
in the inhibition of the CSC expansion of our tumor cells, we have observed the same 
finding as our preliminary data suggest that the mutant has no effect on the survival of WT 
cells. It would be very useful to discover whether the Myc dependency of our tumor model 
might be exploited in vivo as a CSC specific therapy, and to elucidate how it could 
cooperate with p53 restoration strategies. 
Notably, Omomyc, by disrupting the interaction between Myc and Max, functionally 
impairs only the trans-activating activity of Myc and not the trans-repressing. Thus, its 
action would affect the downstream pathways of Myc that we have characterized and that 
mainly concern cell cycle promotion and mitotic proficiency.  
Finally, our findings have clinical implications with respect to the issue of biological 
heterogeneity and tumor targeting. They suggest that the elimination of CSCs might not be 
enough for effective cancer eradication, and that targeting those cellular mechanisms that 
induce reprogramming of tumor cells into cells with CSC properties is also required.
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